Document:

<PAGE>   1

                                                                    Exhibit 10.1

                             COR THERAPEUTICS, INC.

             5.00% CONVERTIBLE SUBORDINATED NOTES DUE MARCH 1, 2007

                               ------------------

                               PURCHASE AGREEMENT

                                                               February 17, 2000

Goldman, Sachs & Co.,
Chase H&Q, A Division of Chase Securities Inc.,
CIBC World Markets Corp.,
FleetBoston Robertson Stephens Inc.,
Warburg Dillon Read LLC,
c/o Goldman, Sachs & Co.,
85 Broad Street,
New York, New York 10004.

Ladies and Gentlemen:

        COR Therapeutics, Inc., a Delaware corporation (the "Company"),
proposes, subject to the terms and conditions stated herein, to issue and sell
to the Purchasers named in Schedule I hereto (the "Purchasers") an aggregate of
$250,000,000 principal amount of the Convertible Subordinated Notes specified
above, convertible into common stock, par value $0.001 ("Stock"), of the Company
(the "Firm Securities") and, at the election of the Purchasers, up to an
aggregate of $50,000,000 additional aggregate principal amount of such Notes
(the "Optional Securities"). The Firm Securities and the Optional Securities
which the Purchasers elect to purchase pursuant to Section 2 hereof are herein
collectively called the "Securities".

        The Purchasers and other holders (including subsequent transferees) of
Securities in registered form without coupons will be entitled to the benefits
of the registration rights agreement, to be dated as of the First Time of
Delivery (as defined in Section 4) (the "Registration Rights Agreement"), by and
among the Company and the Purchasers, in the form attached hereto as Exhibit A.
Pursuant to the Registration Rights Agreement, the Company will agree to file
with the Securities and Exchange Commission (the "Commission") under the
circumstances set forth therein a shelf registration statement (the
"Registration Statement") pursuant to Rule 415 under the Securities Act of 1933,
as amended (the "Securities Act"), relating to the resale of the Securities and
shares of Stock initially issuable upon conversion of the Securities by holders
thereof, and to use its reasonable efforts to cause such shelf registration
statement to be declared effective as provided therein.

        1. The Company represents and warrants to, and agrees with, each of the
Purchasers that:

<PAGE>   2

               (a) (i) An offering circular, dated February 17, 2000 (the
        "Offering Circular"), has been prepared in connection with the offering
        of the Securities and the shares of Stock issuable upon conversion
        thereof. Any reference to the Offering Circular shall be deemed to refer
        to and include the Company's most recent Annual Report on Form 10-K for
        the fiscal year ended December 31, 1998 and Quarterly Report on Form
        10-Q for the quarter ended September 30, 1999, which are attached to and
        made a part of the Offering Circular, and all subsequent documents filed
        by the Company with the Commission pursuant to Section 13(a), 13(c) or
        15(d) of the United States Securities Exchange Act of 1934, as amended
        (the "Exchange Act"), on or prior to the date of the Offering Circular,
        and any reference to the Offering Circular, as amended or supplemented,
        as of any specified date, shall be deemed to include (i) any documents
        filed with the Commission pursuant to Section 13(a), 13(c) or 15(d) of
        the Exchange Act after the date of the Offering Circular and prior to
        such specified date and (ii) any Additional Issuer Information (as
        defined in Section 5(f)) furnished by the Company prior to the
        completion of the distribution of the Securities; and all documents
        filed under the Exchange Act and so deemed to be included the Offering
        Circular or any amendment or supplement thereto are hereinafter called
        the "Exchange Act Reports". The Offering Circular and any amendments or
        supplements thereto did not and will not, as of their respective dates,
        contain an untrue statement of a material fact or omit to state a
        material fact necessary in order to make the statements therein, in
        light of the circumstances under which they were made, not misleading;
        provided, however, that this representation and warranty shall not apply
        to any statements or omissions made in reliance upon and in conformity
        with information furnished in writing to the Company by a Purchaser
        through Goldman, Sachs & Co. expressly for use therein;

                    (ii) The Exchange Act Reports, when they were or are filed
        with the Commission, conformed or will conform in all material respects
        to the applicable requirements of the Exchange Act and the applicable
        rules and regulations of the Commission thereunder, and the Exchange Act
        Reports did not and will not, as of their respective dates, contain an
        untrue statement of a material fact or omit to state a material fact
        necessary in order to make the statements therein, in the light of the
        circumstances under which they were made, not misleading; and

                    (iii) The information provided by the Company pursuant to
        Section 5(f) will not, at the date thereof, contain any untrue statement
        of a material fact or omit to state any material fact necessary in order
        to make the statements therein, in the light of the circumstances under
        which they were made, not misleading;

               (b) The Company has not sustained since the date of the latest
        audited financial statements included in the Offering Circular any
        material loss or interference with its business from fire, explosion,
        flood or other calamity, whether or not covered by insurance, or from
        any labor dispute or court or governmental action, order or decree,
        otherwise than as set forth or contemplated in the Offering Circular;
        and, since the respective dates as of which information is given in the
        Offering Circular, there has not been any decrease in the capital stock
        or increase in long-term debt in excess of $1 million of the Company or
        any material adverse change, or any development involving a prospective
        material adverse change, in or affecting the general affairs,
        management, financial position, stockholders' equity or results of

                                       2
<PAGE>   3

        operations of the Company, otherwise than as set forth or contemplated
        in the Offering Circular;

               (c) The Company has good and marketable title to all material
        personal property owned by it, free and clear of all liens, encumbrances
        and defects except such as are described in the Offering Circular or
        such as do not interfere with the use made and proposed to be made of
        such property by the Company; and any real property and buildings held
        under lease by the Company are held by it under valid, subsisting and
        enforceable leases with such exceptions as are not material and do not
        interfere with the use made and proposed to be made of such property and
        buildings by the Company; the Company owns no real property;

               (d) The Company has been duly incorporated and is validly
        existing as a corporation in good standing under the laws of the State
        of Delaware, with full corporate power and authority to own or lease its
        properties and conduct its business as described in the Offering
        Circular, and has been duly qualified as a foreign corporation for the
        transaction of business and is in good standing under the laws of each
        other jurisdiction in which it owns or leases properties or conducts any
        business so as to require such qualification, or is subject to no
        material liability or disability by reason of the failure to be so
        qualified in any such jurisdiction; the Company has no subsidiaries;

               (e) The Company has an authorized capitalization as set forth in
        the Offering Circular, and all of the issued shares of capital stock of
        the Company have been duly and validly authorized and issued and are
        fully paid and non-assessable; the shares of Stock initially issuable
        upon conversion of the Securities have been duly and validly authorized
        and reserved for issuance and, when issued and delivered in accordance
        with the provisions of the Securities and the Indenture (as defined in
        Section I(f)), will be duly and validly issued, fully paid and
        non-assessable and will conform to the description of the Stock
        contained in the Offering Circular;

               (f) The Securities have been duly authorized and, when issued and
        delivered pursuant to this Agreement, will have been duly executed,
        authenticated, issued and delivered and will constitute valid and
        legally binding obligations of the Company enforceable in accordance
        with their terms and entitled to the benefits provided by the indenture
        to be dated as of February 24, 2000 (the "Indenture") between the
        Company and Firstar Bank, as Trustee (the "Trustee"), under which they
        are to be issued, which will be substantially in the form previously
        delivered to you; the Indenture has been duly authorized and, when
        executed and delivered by the Company and the Trustee, the Indenture
        will constitute a valid and legally binding instrument, enforceable in
        accordance with its terms, subject, as to enforcement, to bankruptcy,
        insolvency, reorganization and other laws of general applicability
        relating to or affecting creditors' rights and to general equity
        principles; and the Securities and the Indenture will conform to the
        descriptions thereof in the Offering Circular and will be in
        substantially the form previously delivered to you;

               (g) None of the transactions contemplated by this Agreement
        (including, without limitation, the use of the proceeds from the sale of
        the Securities) will violate or result in a violation of Section 7 of
        the Exchange Act, or any regulation promulgated thereunder,

                                       3
<PAGE>   4

        including, without limitation, Regulations G, T, U, and X of the Board
        of Governors of the Federal Reserve System;

               (h) Prior to the date hereof, neither the Company nor any of its
        affiliates has taken any action which is designed to or which has
        constituted or which might reasonably have been expected to cause or
        result in stabilization or manipulation of the price of any security of
        the Company in connection with the offering of the Securities;

               (i) The issue and sale of the Securities and the compliance by
        the Company with all of the provisions of the Securities, the
        Registration Rights Agreement, the Indenture and this Agreement and the
        consummation of the transactions herein and therein contemplated will
        not conflict with or result in a breach or violation of any of the terms
        or provisions of, or constitute a default under, any indenture,
        mortgage, deed of trust, loan agreement or other material agreement or
        instrument to which the Company is a party or by which the Company is
        bound or to which any of the property or assets of the Company is
        subject, nor will such action result in any violation of the provisions
        of the Certificate of Incorporation or By-laws of the Company or, except
        as to any violations which would not have a Material Adverse Effect (as
        defined below), any statute or any order, rule or regulation of any
        court or governmental agency or body having jurisdiction over the
        Company or any of its properties; and no consent, approval,
        authorization, order, registration or qualification of or with any such
        court or governmental agency or body is required for the issue and sale
        of the Securities or the consummation by the Company of the transactions
        contemplated by this Agreement, the Registration Rights Agreement or the
        Indenture, except (i) as required pursuant to the Registration Rights
        Agreement, (ii) for the approval of the Stock issuable upon conversion
        of the Securities for quotation on the Nasdaq National Market, and,
        (iii) such consents, approvals, authorizations, registrations or
        qualifications as may be required under state securities or Blue Sky
        laws in connection with the purchase and distribution of the Securities
        by the Purchasers;

               (j) The Company is not in violation of its Certificate of
        Incorporation or By-laws or in default in the performance or observance
        of any material obligation, covenant or condition contained in any
        indenture, mortgage, deed of trust, loan agreement, material lease or
        other material agreement or instrument to which it is a party or by
        which it or any of its properties may be bound;

               (k) The statements set forth in the Offering Circular under the
        captions "Description of the Notes" and "Description of Capital Stock",
        insofar as they purport to constitute a summary of the terms of the
        Securities and the Stock, and under the caption "Underwriting", insofar
        as they purport to describe the provisions of the documents referred to
        therein, accurately and fairly present in all material respects such
        matters and documents (to the same extent as would be required if the
        Offering Circular were a prospectus included in a Registration Statement
        of the Company on Form S-1 under the Securities Act);

               (l) Other than as set forth in the Offering Circular, there are
        no legal or governmental proceedings pending to which the Company is a
        party or of which any property of the Company is the subject which, if
        determined adversely to the Company, would individually or in the
        aggregate have a material adverse effect on the business, prospects,
        financial condition or results of operations of the Company or on the
        ability of the Company to consummate the

                                       4
<PAGE>   5

        transactions contemplated herein (a "Material Adverse Effect"); and, to
        the Company's knowledge, no such proceedings are threatened by
        governmental authorities or by others;

               (m) When the Securities are issued and delivered pursuant to this
        Agreement, the Securities will not be of the same class (within the
        meaning of Rule 144A under the Securities Act) as securities which are
        listed on a national securities exchange registered under Section 6 of
        the Exchange Act or quoted in a U.S. automated inter-dealer quotation
        system;

               (n) The Company is subject to Section 13 or 15(d) of the Exchange
        Act;

               (o) The Company is not, and after giving effect to the offering
        and sale of the Securities, will not be, an "investment company", as
        such term is defined in the United States Investment Company Act of
        1940, as amended (the "Investment Company Act");

               (p) Neither the Company, nor any person acting on its behalf has
        offered or sold the Securities by means of any general solicitation or
        general advertising within the meaning of Rule 502(c) under the
        Securities Act (except that no representation or warranty is made with
        respect to the Purchasers or any persons acting on their behalf);

               (q) Within the preceding six months, neither the Company nor any
        other person acting on behalf of the Company has offered or sold to any
        person any Securities, or any securities of the same or a similar class
        as the Securities, other than Securities offered or sold to the
        Purchasers hereunder. The Company will take reasonable precautions
        designed to insure that any offer or sale, direct or indirect, in the
        United States or to any U.S. person (as defined in Rule 902 under the
        Securities Act) of any Securities or any substantially similar security
        issued by the Company, within six months subsequent to the date on which
        the distribution of the Securities has been completed (as notified to
        the Company by Goldman, Sachs & Co.), is made under restrictions and
        other circumstances reasonably designed not to affect the status of the
        offer and sale of the Securities in the United States and to U.S.
        persons contemplated by this Agreement as transactions exempt from the
        registration provisions of the Securities Act (except that no
        representation or warranty is made with respect to the Purchasers or any
        persons acting on their behalf);

               (r) It is not necessary in connection with the offer, sale and
        delivery of the Securities to the Purchasers, or in connection with the
        initial resale of the Securities by the Purchasers in accordance with
        this Agreement, to register the Securities under the Securities Act or
        to qualify an indenture under the Trust Indenture Act of 1939, as
        amended (the "Trust Indenture Act");

               (s) The Securities have been designated PORTAL eligible
        securities in accordance with the rules and regulations of the National
        Association of Securities Dealers, Inc.;

               (t) The Company has all requisite corporate power to enter into
        this Agreement and the Registration Rights Agreement. This Agreement has
        been and, as of the First Time of Delivery (as defined below), the
        Registration Rights Agreement will have been, duly authorized, executed
        and delivered by the Company and upon such execution by the Company
        (assuming the due authorization, execution and delivery of such
        agreements by the

                                       5
<PAGE>   6

        other parties thereto) this Agreement and the Registration Rights
        Agreement will constitute the valid and binding obligations of the
        Company enforceable against the Company in accordance with the terms
        hereof or thereof, subject, as to enforcement, to bankruptcy,
        insolvency, reorganization and other laws of general applicability
        relating to or affecting creditors' rights and to general equity
        principles, and except as the enforcement of indemnification and
        contribution provisions hereof and thereof may be limited by applicable
        law;

               (u) Except as disclosed in the Offering Circular, there are no
        persons with registration rights or other similar rights to have any
        securities of the Company (other than the Securities and the shares of
        Stock issuable upon conversion thereof) registered under any Securities
        Act registration statement;

               (v) None of the holders of outstanding shares of capital stock of
        the Company and no other person has or will have any preemptive or other
        rights to purchase, subscribe for or otherwise acquire (i) the shares of
        Stock to be issued upon conversion of the Securities or any rights to
        such shares (other than those granted by the holders of the Securities)
        or (ii) as a result of or in connection with the transactions
        contemplated by the Indenture, this Agreement or the Registration Rights
        Agreement, any other capital stock of the Company or rights thereto;

               (w) The Company's directors and executive officers, in each case
        as listed on Exhibit B-1, have entered into a written agreement with the
        Company in the form of Exhibit B hereto (each such agreement, a "Lock-up
        Agreement"), and executed originals of each Lock-up Agreement have been
        delivered to you;

               (x) To the Company's knowledge, Ernst & Young LLP, who have
        certified certain financial statements of the Company, are independent
        public accountants as required by the Securities Act and the rules and
        regulations of the Commission thereunder;

               (y) The Company has reviewed its operations and its interfaces
        with third-party systems to evaluate the extent to which the business or
        operations of the Company will be affected by the Year 2000 Problem. As
        a result of such review, the Company represents and warrants that the
        disclosure in the Offering Circular relating to the Year 2000 Problem is
        accurate and complies in all material respects with the rules and
        regulations under the Securities Act (to the same extent as would be
        required if the Offering Circular were a prospectus included in a
        Registration Statement of the Company on Form S-1 under the Securities
        Act). The "Year 2000 Problem" as used herein means any significant risk
        that computer hardware or software used in the receipt, transmission,
        processing, manipulation, storage, retrieval, retransmission or other
        utilization of data or in the operation of mechanical or electrical
        systems of any kind will not, in the case of dates or time periods
        occurring after December 31, 1999, function at least as effectively as
        in the case of dates or time periods occurring prior to January 1, 2000;

               (z) (i) The Company owns, or possesses adequate rights to use,
        all material trademarks, service marks, trade names, trademark
        registrations, service mark registrations, domain names and copyrights
        necessary for the conduct of its business and, except as set

                                       6
<PAGE>   7

        forth in the Offering Circular, has not received any notice of any claim
        of conflict with any such rights of others except as would not have a
        Material Adverse Effect; and (ii) to the Company's knowledge, the
        Company has not infringed and is not infringing any trademarks, service
        marks, trade names, trademark registrations, service mark registrations,
        domain names or copyrights, which infringement could reasonably be
        expected to result in any Material Adverse Effect;

               (aa) (i) The Company owns or possesses adequate rights to use,
        all material patents necessary for the conduct of its business; (ii) to
        the Company's knowledge, no valid United States patent is or would be
        infringed by the activities of the Company, except as would not have a
        Material Adverse Effect; (iii) except as set forth in the Offering
        Circular, there are no actions, suits or judicial proceedings pending
        relating to patents or proprietary information to which the Company is a
        party or of which any property of the Company is subject, and, to the
        knowledge of the Company, no actions, suits or judicial proceedings are
        threatened in writing by governmental authorities or others, in each
        case except as would not result in any Material Adverse Effect; and (iv)
        except as set forth in the Offering Circular or as would not result in
        any Material Adverse Effect, the Company has not been notified in
        writing that the Company is infringing or otherwise violating the
        patents or other intellectual property of others and is not aware of any
        rights of third parties to any of the Company's material patent
        applications, license patents or licenses that in any case could affect
        materially the use thereof by the Company;

               (bb) The Company carries, or is covered by, insurance as is
        customary for companies similarly situated and engaged in similar
        businesses in similar industries;

               (cc) No labor disturbance by the employees of the Company exists
        or, to the knowledge of the Company, is imminent which might be expected
        to have a Material Adverse Effect; and

               (dd) The Company is in compliance with all rules, laws and
        regulations relating to the use, treatment, storage and disposal of
        toxic substances and protection of health or the environment
        ("Environmental Laws") which are applicable to its business except for
        failure to comply which would not have a Material Adverse Effect. The
        Company has received no written notice from any governmental authority
        or third party of an asserted claim under Environmental Laws, which
        claim is required to be disclosed in the Offering Circular. To its
        knowledge, the Company has not conducted any activity which would
        require it to make material capital expenditures to comply with
        Environmental Laws. No property which is owned, leased or occupied by
        the Company has been designated a Superfund site pursuant to the
        Comprehensive Response, Compensation, and Liability Act of 1980, as
        amended (42 U.S.C. ss. 9601, et seq.), or otherwise designated as a
        contaminated site (which designation as a contaminated site would be
        expected to be material to the Company) under applicable state or local
        law.

        2. Subject to the terms and conditions herein set forth, (a) the Company
agrees to issue and sell to each of the Purchasers, and each of the Purchasers
agrees, severally and not jointly, to purchase from the Company, at a purchase
price of 96.5% of the principal amount thereof, plus accrued interest, if any,
from February 24, 2000 to the First Time of Delivery hereunder, the principal
amount of Firm Securities set forth opposite the name of such Purchaser in
Schedule I hereto, and

                                       7
<PAGE>   8
(b) in the event and to the extent that you shall exercise the election to
purchase Optional Securities as provided below, the Company agrees to issue and
sell to each of the Purchasers, and each of the Purchasers agrees, severally and
not jointly, to purchase from the Company, at the same purchase price set forth
in clause (a) of this Section 2, the aggregate principal amount of the Optional
Securities as to which such election shall have been exercised (to be adjusted
by you so as to eliminate denominations of less than U.S.$1,000) determined by
multiplying such aggregate principal amount of Optional Securities by a
fraction, the numerator of which is the maximum aggregate principal amount of
Optional Securities which such Purchaser is entitled to purchase as set forth
opposite the name of such Purchaser in Schedule I hereto and the denominator of
which is the maximum aggregate principal amount of Optional Securities which all
of the Purchasers are entitled to purchase hereunder.

        The Company hereby grants to the Purchasers the right to purchase at
their election up to $50,000,000 aggregate principal amount of Optional
Securities, at the purchase price set forth in clause (a) of the first paragraph
of this Section 2, for the sole purpose of covering sales of Securities in
excess of the number of Firm Securities. Any such election to purchase Optional
Securities may be exercised by written notice from you to the Company, given
within a period of 30 calendar days after the date of this Agreement, setting
forth the aggregate principal amount of Optional Securities to be purchased and
the date on which such Optional Securities are to be delivered, as determined by
you but in no event earlier than the First Time of Delivery or, unless you and
the Company otherwise agree in writing, earlier than two or later than ten
business days after the date of such notice.

        3. Upon the authorization by you of the release of the Securities, the
several Purchasers propose to offer the Securities for sale upon the terms and
conditions set forth in this Agreement and the Offering Circular and each
Purchaser hereby represents and warrants to, and agrees with the Company that:

        (a) It will offer and sell the Securities only to: persons who it
reasonably believes are "qualified institutional buyers" ("QIBs") within the
meaning of Rule 144A under the Securities Act in transactions meeting the
requirements of Rule 144A;

        (b) It is an institution that is an "accredited investor" within the
meaning of Rule 501 under the Securities Act; and

        (c) It will not offer or sell the Securities by any form of general
solicitation or general advertising, including but not limited to the methods
described in Rule 502(c) under the Securities Act.

        4. (a) The Securities will be represented by one or more definitive
global Securities in book-entry form which will be deposited by or on behalf of
the Company with The Depository Trust Company ("DTC") or its designated
custodian. The Company will deliver the Securities to the Purchasers, against
payment by the Purchasers of the purchase price therefor by wire transfer to the
Company of Federal (same day) funds, by causing DTC to credit the Securities to
the account of the Purchasers at DTC. The Company will cause the certificates
representing the Securities to be made available to the Purchasers for checking
at least twenty-four hours prior to the Time of Delivery (as defined below) at
the office of DTC or its designated custodian (the "Designated Office"). The
time and date of such delivery and payment shall be, with respect to Firm
Securities, 7:00 a.m., San

                                       8
<PAGE>   9

Francisco time, on February 24, 2000 or such other time and date as the
Purchasers and the Company may agree upon in writing and, with respect to the
Optional Securities, 7:00 a.m. San Francisco time, on the date specified by the
Purchasers in the written notice given by the Purchasers of the Purchasers'
election to purchase such Optional Securities, or such other time and date as
the Purchasers and the Company may agree upon in writing. Such time and date for
delivery of the Firm Securities is herein called the "First Time of Delivery",
such time and date for delivery of the Optional Securities, if not the First
Time of Delivery, is herein called the "Second Time of Delivery", and each such
time and date for delivery is herein called a "Time of Delivery".

        (b) The documents to be delivered at each Time of Delivery by or on
behalf of the parties hereto pursuant to Section 7 hereof, including the
cross-receipt for the Securities and any additional documents requested by the
Purchasers pursuant to Section 7(j) hereof, will be delivered at such time and
date at the offices of Cooley Godward LLP, 3000 El Camino Real, Palo Alto,
California 94306 (the "Closing Location"), and the Securities will be delivered
at the Designated Office, all at the Time of Delivery. A meeting will be held at
the Closing Location at 2:00 p.m., San Francisco time, on the New York Business
Day next preceding the Time of Delivery, at which meeting the final drafts of
the documents to be delivered pursuant to the preceding sentence will be
available for review by the parties hereto. For the purposes of this Section 4,
"New York Business Day" shall mean each Monday, Tuesday, Wednesday, Thursday and
Friday which is not a day on which banking institutions in New York are
generally authorized or obligated by law or executive order to close.

        5. The Company agrees with each of the Purchasers:

        (a) To prepare the Offering Circular in a form approved by you; to make
no amendment or any supplement to the Offering Circular which shall be
reasonably disapproved by you promptly after reasonable notice thereof; and to
furnish you with copies thereof;

        (b) Promptly from time to time to take such action as you may reasonably
request to qualify the Securities and the shares of Stock issuable upon
conversion of the Securities for offering and sale under the securities laws of
such U.S. jurisdictions as you may request and to comply with such laws so as to
permit the continuance of sales and dealings therein in such U.S. jurisdictions
for as long as may be necessary to complete the distribution of the Securities,
provided that in connection therewith the Company shall not be required to
qualify as a foreign corporation or to file a general consent to service of
process or taxation in any jurisdiction;

        (c) To furnish the Purchasers with four copies of the Offering Circular
and each amendment or supplement thereto signed by an authorized officer of the
Company with the independent accountants' report in the Offering Circular, and
any amendment or supplement containing amendments to the financial statements
covered by such report, signed by the accountants, and additional copies thereof
in such quantities as you may from time to time reasonably request, and if, at
any time prior to the expiration of nine months after the date of the Offering
Circular, any event shall have occurred as a result of which the Offering
Circular as then amended or supplemented would include an untrue statement of a
material fact or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made
when such Offering Circular is delivered, not misleading, or, if for any other
reason it shall be necessary or desirable during such same period to amend or
supplement the Offering Circular, to notify you and upon your request to prepare
and furnish without charge to each Purchaser and to any

                                       9
<PAGE>   10

dealer in securities as many copies as you may from time to time reasonably
request of an amended Offering Circular or a supplement to the Offering Circular
which will correct such statement or omission or effect such compliance;

        (d) During the period beginning from the date of the Offering Circular
and continuing until the date 90 days after the date of the Offering Circular,
not to offer, sell, contract to sell or otherwise dispose of, except as provided
hereunder, any securities of the Company that are substantially similar to the
Securities or the Stock, including but not limited to any securities that are
convertible into or exchangeable for, or that represent the right to receive,
Stock or any such substantially similar securities other than (i) pursuant to
employee stock option plans and employee stock purchase plans existing on, or
upon the conversion or exchange of convertible or exchangeable securities
outstanding as of, the date of this Agreement, or upon conversion of the
Securities, (ii) as consideration for acquisitions of businesses, (iii) pursuant
to equipment or lease or facilities financing activities entered into in the
ordinary course of business, or (iv) to a strategic partner of the Company in
conjunction with an agreement involving a technical, manufacturing and/or
marketing collaboration occurring after the date of the Offering Circular,
provided that each recipient of shares pursuant to these clauses (ii) through
(iv) agrees that all such shares remain subject to restrictions substantially
similar to those contained in this subsection; and that the Company will use
reasonable efforts to cause each person who has entered into a Lock-up Agreement
to comply therewith, will not grant any waivers or consents to non-compliance
therewith and will enforce its rights under each such agreement, in each case
unless and to the extent that it shall have obtained your prior consent;

        (e) Not to be or become, at any time prior to the expiration of three
years after the Time of Delivery, an open-end investment company, unit
investment trust, closed-end investment company or face-amount certificate
company that is or is required to be registered under Section 8 of the
Investment Company Act;

        (f) At any time when the Company is not subject to Section 13 or 15(d)
of the Exchange Act, for the benefit of holders from time to time of Securities,
to furnish at its expense, upon request, to holders of Securities and
prospective purchasers of securities information (the "Additional Issuer
Information") satisfying the requirements of subsection (d)(4)(i) of Rule 144A
under the Securities Act;

        (g) To use its reasonable efforts to cause the Securities to be eligible
for the PORTAL trading system of the National Association of Securities Dealers,
Inc.;

        (h) To furnish to the holders of the Securities as soon as practicable
after the end of each fiscal year an annual report (including a balance sheet
and statements of income, stockholders' equity and cash flows of the Company and
its consolidated subsidiaries certified by independent public accountants) and,
as soon as practicable after the end of each of the first three quarters of each
fiscal year (beginning with the fiscal quarter ending after the date of the
Offering Circular), consolidated summary financial information of the Company
and its subsidiaries for such quarter in reasonable detail;

        (i) During a period of five years from the date of the Offering
Circular, provided any of the Securities are then outstanding, to furnish to you
copies of all reports or other communications (financial or other) furnished to
stockholders of the Company, and to deliver to you (i) as soon as they

                                       10
<PAGE>   11

are available, copies of any reports and financial statements furnished to or
filed with the Commission or any securities exchange on which the Securities or
any class of securities of the Company is listed, provided that any reports,
financial statements or other communications that are available by EDGAR need
not be furnished; and (ii) such additional information concerning the business
and financial condition of the Company as you may from time to time reasonably
request (such financial statements to be on a consolidated basis to the extent
the accounts of the Company and its subsidiaries are consolidated in reports
furnished to its stockholders generally or to the Commission);

        (j) During the period of two years after the Time of Delivery, the
Company will not, and will not permit any of its "affiliates" (as defined in
Rule 144 under the Securities Act) to, resell any of the Securities which
constitute "restricted securities" under Rule 144 that have been reacquired by
any of them;

        (k) To use the net proceeds received by it from the sale of the
Securities pursuant to this Agreement in the manner specified in the Offering
Circular under the caption "Use of Proceeds";

        (l) To reserve and keep available at all times, free of preemptive
rights, shares of Stock for the purpose of enabling the Company to satisfy any
obligations to issue shares of its Stock upon conversion of the Securities; and

        (m) To use its reasonable efforts to list, subject to notice of
issuance, the shares of Stock issuable upon conversion of the Securities on the
Nasdaq National Market.

        6. The Company covenants and agrees with the several Purchasers that the
Company will pay or cause to be paid the following: (i) the fees, disbursements
and expenses of the Company's counsel and accountants in connection with the
issue of the Securities and the shares of Stock issuable upon conversion of the
Securities and all other expenses in connection with the preparation, printing
and filing of the Offering Circular and any amendments and supplements thereto
and the mailing and delivering of copies thereof to the Purchasers and dealers;
(ii) the cost of printing or producing the Blue Sky and Legal Investment
Memoranda, if any, in connection with the offering, purchase, sale and delivery
of the Securities; (iii) all expenses in connection with the qualification of
the Securities and the shares of Stock issuable upon conversion of the
Securities for offering and sale under state securities laws as provided in
Section 5(b) hereof, including the fees and disbursements of counsel for the
Purchasers in connection with such qualification and in connection with the Blue
Sky and legal investment surveys; (iv) any fees charged by securities rating
services for rating the Securities; (v) the cost of preparing the Securities;
(vi) the fees and expenses of the Trustee and any agent of the Trustee and the
fees and disbursements of counsel for the Trustee in connection with the
Indenture and the Securities; (vii) any cost incurred in connection with the
designation of the Securities for trading in PORTAL and the listing of the
shares of Stock issuable upon conversion of the Securities on the Nasdaq
National Market; and (viii) all other costs and expenses incident to the
performance of its obligations hereunder which are not otherwise specifically
provided for in this Section. It is understood, however, that, except as
provided in this Section, and Sections 8 and 11 hereof, the Purchasers will pay
all of their own costs and expenses, including the fees of their counsel,
transfer taxes on resale of any of the Securities by them, and any advertising
expenses connected with any offers they may make.

                                       11
<PAGE>   12

        7. The obligations of the Purchasers hereunder, as to the Securities to
be delivered at each Time of Delivery, shall be subject, in their discretion, to
the condition that all representations and warranties and other statements of
the Company herein are, at and as of such Time of Delivery, true and correct,
the condition that the Company shall have performed all of its obligations
hereunder theretofore to be performed, and the following additional conditions:

        (a) Sullivan & Cromwell, counsel for the Purchasers, shall have
furnished to you such opinion or opinions, dated such Time of Delivery, with
respect to such matters as you may reasonably request, and such counsel shall
have received such papers and information as they may reasonably request to
enable them to pass upon such matters;

        (b) Cooley Godward LLP, counsel for the Company, and Patrick Broderick,
Senior Vice President and General Counsel of the Company, shall have furnished
to you their written opinions, dated such Time of Delivery, in form and
substance satisfactory to you, to the effect that:

        In the case of the opinion of Cooley Godward LLP:

               (i) The Company has been duly incorporated and is validly
        existing as a corporation in good standing under the laws of Delaware,
        with full corporate power and authority to own or lease its properties
        and to conduct its business as described in the Offering Circular;

               (ii) The Company has an authorized capitalization as set forth in
        the Offering Circular, and all of the issued shares of capital stock of
        the Company have been duly and validly authorized and issued and are
        fully paid and nonassessable; and the shares of Stock initially issuable
        upon conversion of the Securities have been duly and validly authorized
        and reserved for issuance and, when issued and delivered in accordance
        with the provisions of the Securities and the Indenture, will be duly
        and validly issued and fully paid and non-assessable, and will conform
        to the description of the Stock contained in the Offering Circular under
        the caption "Description of Capital Stock";

               (iii) To such counsel's knowledge, the Company is duly qualified
        to do business as a foreign corporation and is in good standing as a
        foreign corporation authorized to do business in the State of
        California;

               (iv) To such counsel's knowledge and other than as set forth in
        the Offering Circular, there are no legal or governmental proceedings
        pending to which the Company is a party or of which any property of the
        Company is subject that would be required to be described in the
        Offering Circular, to the same extent as would be required if the
        Offering Circular were a prospectus included in a Registration Statement
        of the Company on Form S-1 under the Securities Act;

               (v) This Agreement and the Registration Rights Agreement have
        been duly authorized, executed and delivered by the Company;

               (vi) The Securities have been duly authorized, executed,
        authenticated, issued and delivered and constitute valid and legally
        binding obligations of the Company enforceable in accordance with their
        terms and entitled to the benefits provided by the Indenture, subject,
        as

                                       12
<PAGE>   13

        to enforcement, to bankruptcy, insolvency, reorganization and other laws
        of general applicability relating to or affecting creditors' rights and
        to general equity principles; and the Securities and the Indenture
        conform to the descriptions thereof contained in the Offering Circular
        under the caption "Description of the Notes" (such counsel being
        entitled to rely on the opinion of Sullivan & Cromwell as to matters of
        New York law);

               (vii) The Indenture has been duly authorized, executed and
        delivered by the Company and, assuming due authorization, execution and
        delivery by the Trustee, constitutes a valid and legally binding
        instrument, enforceable in accordance with its terms, subject, as to
        enforcement, to bankruptcy, insolvency, reorganization and other laws of
        general applicability relating to or affecting creditors' rights and to
        general equity principles (such counsel being entitled to rely on the
        opinion of Sullivan & Cromwell as to matters of New York law);

               (viii) The issue and sale of the Securities and the compliance by
        the Company with all of the provisions of the Securities, the Indenture,
        the Registration Rights Agreement and this Agreement and the
        consummation of the transactions herein and therein contemplated will
        not conflict with or result in a breach or violation of any of the terms
        or provisions of, or constitute a default under, any indenture,
        mortgage, deed of trust, loan agreement or other agreement or instrument
        listed by the Company as an exhibit to the Company's Annual Report on
        Form 10-K for the year ended December 31, 1998, nor will such actions
        result in any violation of the provisions of the Certificate of
        Incorporation or By-laws of the Company or any statute or, to such
        counsel's knowledge, any rule or regulation of any governmental agency
        or body having jurisdiction over the Company or any of its properties
        (except for the securities or Blue Sky laws of the various states as to
        which such counsel need not express any opinion) or, to such counsel's
        knowledge, any order of any court entered against the Company;

               (ix) No consent, approval, authorization, order, registration or
        qualification of or with any governmental agency or body is required for
        the offer and sale of the Securities or the consummation by the Company
        of the transactions contemplated by this Agreement, the Registration
        Rights Agreement or the Indenture, except such as may be required under
        the Securities Act and blue sky laws of the various states in connection
        with registration, pursuant to the Registration Rights Agreement, of the
        Securities and the shares of Stock issuable upon conversion of the
        Securities and such consents, approvals, authorizations, registrations
        or qualifications as may be required under state securities or Blue Sky
        laws in connection with the purchase and distribution of the Securities
        by the Purchasers;

               (x) The statements set forth in the Offering Circular under the
        captions "Description of the Notes" and "Description of Capital Stock",
        insofar as they purport to constitute a summary of the terms of the
        Securities and the Stock, and under the captions "Certain United States
        Federal Income Tax Consequences", insofar as they purport to describe
        the provisions of the laws and documents referred to therein, fairly
        present in all material respects such legal matters and documents (to
        the same extent as would be required if the Offering Circular were a
        prospectus included in a Registration Statement of the Company on Form
        S-1 under the Securities Act);

               (xi) No registration of the Securities or the shares of Stock
        issued upon conversion of the Securities under the Securities Act, and
        no qualification of an indenture under the Trust

                                       13
<PAGE>   14

        Indenture Act with respect to the Securities, is required for the offer
        and sale by the Company and the offer and initial resale of the
        Securities by the Purchasers in the manner contemplated by this
        Agreement assuming (i) the accuracy of, and compliance with, the
        Purchasers' representations and agreements contained in Section 3 of the
        Purchase Agreement, (ii) the accuracy of the representations of the
        Company set forth in Sections 1(m), 1(n), 1(p) and 1(q) of the Purchase
        Agreement and (iii) the Securities are sold pursuant to the Offering
        Circular;

               (xii) The Company is not an "investment company", as such term is
        defined in the Investment Company Act;

               (xiii) To such counsel's knowledge, the Company is licensed to
        use, or owns, each patent application and patent listed on Exhibit 2 to
        its opinion (such exhibit to be consistent with the draft exhibit
        previously furnished to Sullivan & Cromwell) (the "Patent Portfolio");

               (xiv) To such counsel's knowledge, except as otherwise described
        in Exhibit 2, no third party has any rights to the patent applications
        and patents listed in the Patent Portfolio for the manufacture, use or
        sale of Integrelin;

               (xv) The Company's United States patent applications listed in
        the Patent Portfolio have been prepared and filed in the United States
        Patent and Trademark Office (the "USPTO") in a form and with
        accompanying papers that are acceptable to the USPTO for the purposes of
        according each such application a filing date and serial number, and of
        placing each such application in condition for eventual examination on
        the merits as to patentability. For each such United States application,
        an Official Filing Receipt has been received from the USPTO. As to each
        of such applications, such counsel is not aware of any material defect
        of form in preparation or filing; and all United States patent
        applications in the Patent Portfolio have been issued as United States
        patents.

               (xvi) The statements contained in the Offering Circular under the
        caption "Risk Factors--If we are unable to protect our patents and
        proprietary rights we may not be able to compete successfully" and in
        the Form 10-K attached to the Offering Circular under the caption
        "Patents, Proprietary Rights and Licenses" as they pertain to the Patent
        Portfolio, insofar as such statements constitute matters of law, are a
        fair and accurate summary of the matters set forth therein, to the
        extent required under the Act and the applicable Rules and Regulations;

               (xvii) To such counsel's knowledge, other than as set forth in
        the Offering Circular, the Company has received no notice of any
        infringement of, conflict with or misappropriation by a third party of
        any claim for which patent applications have been filed with respect to
        the Patent Portfolio or notice of any unresolved infringement of, or
        conflict with or proceedings against or misappropriation by the Company
        of any patents, trade secrets, trademarks, trade names, copyrights or
        other proprietary rights of a third party, which, either individually or
        in the aggregate, is material to the Company;

                                       14
<PAGE>   15

               (xviii) To such counsel's knowledge, the Company or its licensor
        is the sole assignee of record for each patent application and patent
        listed in the Patent Portfolio. Except as otherwise noted in the Patent
        Portfolio, for each of the United States patent applications and patents
        listed in the Patent Portfolio, the assignments by the named inventors
        have been submitted to the USPTO and those assignments have been
        recorded in the Patent Office title records; and

               (xix) To such counsel's knowledge, as to each of the Company's
        foreign patent applications listed in the Patent Portfolio, the
        applications have either (a) except as noted in the Patent Portfolio,
        been submitted to patent firms in the respective foreign countries with
        instructions to file the applications in the patent offices of those
        countries naming the Company as the applicant of record, or (b) as to
        certain Patent Cooperation Treaty applications, been submitted directly
        to the relevant receiving office naming the Company as the applicant of
        record. To such counsel's knowledge and except as noted in the Patent
        Portfolio, as to each of such applications, the Company has not received
        notice from any foreign filing authority of any material defect of form
        in preparation or filing that the Company has not cured within the
        relevant cure period;

               Subject to the final sentence of this paragraph, such counsel
        shall also state that they have no reason to believe that the Offering
        Circular and any further amendments or supplements thereto made by the
        Company prior to such Time of Delivery (other than the financial
        statements, including supporting schedules and other financial data
        derived from accounting records and included therein, as to which such
        counsel need express no opinion) contained as of its date or contains as
        of such Time of Delivery an untrue statement of a material fact or
        omitted or omits, as the case may be, to state a material fact necessary
        to make the statements therein, in the light of the circumstances under
        which they were made, not misleading. Such counsel will be required to
        provide the statement described in this paragraph only if counsel for
        the Purchasers is concurrently providing a similar statement to the
        Purchasers pursuant to Section 7(a).

               The opinion of Cooley Godward LLP described in this Section 7(b)
        shall be rendered to you at the request of the Company and shall so
        state therein. In providing the statement with respect to the matters
        covered in the last paragraph of Section 7(b), Cooley Godward LLP may
        state that its statement and belief are based upon its participation in
        the preparation, together with the Purchasers, Purchaser's counsel and
        the Company's independent accountants, of the Offering Circular and any
        amendments and supplements thereto and review and discussion of the
        contents thereof, but are without independent check or verification
        except as specified;

               In the case of the opinion of Patrick Broderick:

               (i) The Exchange Reports (other than the financial statements and
        related schedules therein, as to which such counsel need express no
        opinion), when they were filed with the Commission, complied as to form
        in all material respects with the requirements of the Exchange Act, and
        the rules and regulations of the Commission thereunder; and such counsel
        has no reason to believe that any of such documents, when they were so
        filed, contained an

                                       15
<PAGE>   16

        untrue statement of a material fact or omitted to state a material fact
        necessary in order to make the statements therein, in the light of the
        circumstances under which they were made when such documents were so
        filed, not misleading;

        (c) On the date of the Offering Circular prior to the execution of this
Agreement and also at such Time of Delivery, Ernst & Young LLP shall have
furnished to you a letter or letters, dated the respective dates of delivery
thereof, in form and substance satisfactory to you, to the effect set forth in
Annex I hereto;

        (d) (i) The Company shall not have sustained since the date of the
latest audited financial statements included in the Offering Circular any loss
or interference with its business from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree, otherwise than as set forth or
contemplated in the Offering Circular, and (ii) since the respective dates as of
which information is given in the Offering Circular there shall not have been
any change in the capital stock or long-term debt of the Company or any change,
or any development involving a prospective change, in or affecting the general
affairs, management, financial position, stockholders' equity or results of
operations of the Company, otherwise than as set forth or contemplated in the
Offering Circular, the effect of which, in any such case described in clause (i)
or (ii), is in your judgment so material and adverse as to make it impracticable
or inadvisable to proceed with the offering or the delivery of the Securities on
the terms and in the manner contemplated in this Agreement and in the Offering
Circular;

        (e) On or after the date hereof (i) no downgrading shall have occurred
in the rating accorded the Company's debt securities by any "nationally
recognized statistical rating organization", as that term is defined by the
Commission for purposes of Rule 436(g)(2) under the Securities Act, and (ii) no
such organization shall have publicly announced that it has under surveillance
or review, with possible negative implications, its rating of any of the
Company's debt securities;

        (f) On or after the date hereof there shall not have occurred any of the
following: (i) a suspension or material limitation in trading in securities
generally on the New York Stock Exchange or on the Nasdaq National Market; (ii)
a suspension or material limitation in trading in the Company's securities on
the Nasdaq National Market; (iii) a general moratorium on commercial banking
activities declared by either Federal or New York State authorities; or (iv) the
outbreak or escalation of hostilities involving the United States or the
declaration by the United States of a national emergency or war, if the effect
of any such event specified in this clause (iv) in the judgment of the
Representatives makes it impracticable or inadvisable to proceed with the
offering or the delivery of the Securities on the terms and in the manner
contemplated in the Offering Circular;

        (g) The Securities shall have been designated for trading on PORTAL;

        (h) Each Lock-up Agreement shall have been duly executed and delivered
to the Company and you, and there shall have occurred no breach of any Lock-up
Agreement;

        (i) The shares of Stock issuable upon conversion of the Securities shall
have been duly listed, subject to notice of issuance, on the Nasdaq National
Market; and

                                       16
<PAGE>   17

        (j) The Company shall have furnished or caused to be furnished to you at
such Time of Delivery certificates of officers of the Company satisfactory to
you as to the accuracy of the representations and warranties of the Company
herein at and as of such Time of Delivery, as to the performance by the Company
of all of its obligations hereunder to be performed at or prior to such Time of
Delivery, and as to such other matters as you may reasonably request.

        8. (a) The Company will indemnify and hold harmless each Purchaser
against any losses, claims, damages or liabilities, joint or several, to which
such Purchaser may become subject, under the Securities Act or otherwise,
insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon an untrue statement or alleged untrue
statement of a material fact contained in any preliminary offering circular or
the Offering Circular, or any amendment or supplement thereto, or arise out of
or are based upon the omission or alleged omission to state therein a material
fact necessary to make the statements therein not misleading, and will reimburse
each Purchaser for any legal or other expenses reasonably incurred by such
Purchaser in connection with investigating or defending any such action or claim
as such expenses are incurred; provided, however, that the Company shall not be
liable in any such case to the extent that any such loss, claim, damage or
liability arises out of or is based upon an untrue statement or alleged untrue
statement or omission or alleged omission made in any preliminary offering
circular or the Offering Circular or any such amendment or supplement in
reliance upon and in conformity with written information furnished to the
Company by any Purchaser through Goldman, Sachs & Co. expressly for use therein.

        (b) Each Purchaser will indemnify and hold harmless the Company against
any losses, claims, damages or liabilities to which the Company may become
subject, under the Securities Act or otherwise, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based
upon an untrue statement or alleged untrue statement of a material fact
contained in any preliminary offering circular or the Offering Circular, or any
amendment or supplement thereto, or arise out of or are based upon the omission
or alleged omission to state therein a material fact or necessary to make the
statements therein not misleading, in each case to the extent, but only to the
extent, that such untrue statement or alleged untrue statement or omission or
alleged omission was made in any preliminary offering circular or the Offering
Circular or any such amendment or supplement in reliance upon and in conformity
with written information furnished to the Company by such Purchaser through
Goldman, Sachs & Co. expressly for use therein; and will reimburse the Company
for any legal or other expenses reasonably incurred by the Company in connection
with investigating or defending any such action or claim as such expenses are
incurred.

        (c) Promptly after receipt by an indemnified party under subsection (a)
or (b) above of notice of the commencement of any action, such indemnified party
shall, if a claim in respect thereof is to be made against the indemnifying
party under such subsection, notify the indemnifying party in writing of the
commencement thereof; but the omission so to notify the indemnifying party shall
not relieve it from any liability which it may have to any indemnified party
otherwise than under such subsection. In case any such action shall be brought
against any indemnified party and it shall notify the indemnifying party of the
commencement thereof, the indemnifying party shall be entitled to participate
therein and, to the extent that it shall wish, jointly with any other
indemnifying party similarly notified, to assume the defense thereof, with
counsel reasonably satisfactory to such indemnified party (who shall not, except
with the consent of the indemnified party, be counsel to the indemnifying
party), and, after notice from the indemnifying party to such indemnified party
of its

                                       17
<PAGE>   18

election so to assume the defense thereof, the indemnifying party shall not be
liable to such indemnified party under such subsection for any legal expenses of
other counsel or any other expenses, in each case subsequently incurred by such
indemnified party, in connection with the defense thereof other than reasonable
costs of investigation. No indemnifying party shall, without the written consent
of the indemnified party, effect the settlement or compromise of, or consent to
the entry of any judgment with respect to, any pending or threatened action or
claim in respect of which indemnification or contribution may be sought
hereunder (whether or not the indemnified party is an actual or potential party
to such action or claim) unless such settlement, compromise or judgment (i)
includes an unconditional release of the indemnified party from all liability
arising out of such action or claim and (ii) does not include a statement as to,
or an admission of, fault, culpability or a failure to act, by or on behalf of
any indemnified party.

        (d) If the indemnification provided for in this Section 8 is unavailable
to or insufficient to hold harmless an indemnified party under subsection (a) or
(b) above in respect of any losses, claims, damages or liabilities (or actions
in respect thereof) referred to therein, then each indemnifying party shall
contribute to the amount paid or payable by such indemnified party as a result
of such losses, claims, damages or liabilities (or actions in respect thereof)
in such proportion as is appropriate to reflect the relative benefits received
by the Company on the one hand and the Purchasers on the other from the offering
of the Securities. If, however, the allocation provided by the immediately
preceding sentence is not permitted by applicable law or if the indemnified
party failed to give the notice required under subsection (c) above, then each
indemnifying party shall contribute to such amount paid or payable by such
indemnified party in such proportion as is appropriate to reflect not only such
relative benefits but also the relative fault of the Company on the one hand and
the Purchasers on the other in connection with the statements or omissions which
resulted in such losses, claims, damages or liabilities (or actions in respect
thereof), as well as any other relevant equitable considerations. The relative
benefits received by the Company on the one hand and the Purchasers on the other
shall be deemed to be in the same proportion as the total net proceeds from the
offering (before deducting expenses) received by the Company bear to the total
underwriting discounts and commissions received by the Purchasers, in each case
as set forth in the Offering Circular. The relative fault shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement
of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company on the one hand or the Purchasers
on the other and the parties' relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission. The Company
and the Purchasers agree that it would not be just and equitable if contribution
pursuant to this subsection (d) were determined by pro rata allocation (even if
the Purchasers were treated as one entity for such purpose) or by any other
method of allocation which does not take account of the equitable considerations
referred to above in this subsection (d). The amount paid or payable by an
indemnified party as a result of the losses, claims, damages or liabilities (or
actions in respect thereof) referred to above in this subsection (d) shall be
deemed to include any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any such action
or claim. Notwithstanding the provisions of this subsection (d), no Purchaser
shall be required to contribute any amount in excess of the amount by which the
total price at which the Securities underwritten by it and distributed to
investors were offered to investors exceeds the amount of any damages which such
Purchaser has otherwise been required to pay by reason of such untrue or alleged
untrue statement or omission or alleged omission. The Purchasers' obligations in
this subsection (d) to contribute are several in proportion to their respective
underwriting obligations and not joint.

                                       18
<PAGE>   19

        (e) The obligations of the Company under this Section 8 shall be in
addition to any liability which the Company may otherwise have and shall extend,
upon the same terms and conditions, to each person, if any, who controls any
Purchaser within the meaning of the Securities Act; and the obligations of the
Purchasers under this Section 8 shall be in addition to any liability which the
respective Purchasers may otherwise have and shall extend, upon the same terms
and conditions, to each officer and director of the Company and to each person,
if any, who controls the Company within the meaning of the Securities Act.

        9. (a) If any Purchaser shall default in its obligation to purchase the
Securities which it has agreed to purchase hereunder, you may in your discretion
arrange for you or another party or other parties to purchase such Securities on
the terms contained herein. If within thirty-six hours after such default by any
Purchaser you do not arrange for the purchase of such Securities, then the
Company shall be entitled to a further period of thirty-six hours within which
to procure another party or other parties satisfactory to you to purchase such
Securities on such terms. In the event that, within the respective prescribed
periods, you notify the Company that you have so arranged for the purchase of
such Securities, or the Company notifies you that it has so arranged for the
purchase of such Securities, you or the Company shall have the right to postpone
the Time of Delivery for a period of not more than seven days, in order to
effect whatever changes may thereby be made necessary in the Offering Circular,
or in any other documents or arrangements, and the Company agrees to prepare
promptly any amendments to the Offering Circular which in your opinion may
thereby be made necessary. The term "Purchaser" as used in this Agreement shall
include any person substituted under this Section with like effect as if such
person had originally been a party to this Agreement with respect to such
Securities.

        (b) If, after giving effect to any arrangements for the purchase of the
Securities of a defaulting Purchaser or Purchasers by you and the Company as
provided in subsection (a) above, the aggregate principal amount of such
Securities which remains unpurchased does not exceed one-eleventh of the
aggregate principal amount of all the Securities, then the Company shall have
the right to require each non-defaulting Purchaser to purchase the principal
amount of Securities which such Purchaser agreed to purchase hereunder and, in
addition, to require each non-defaulting Purchaser to purchase its pro rata
share (based on the principal amount of Securities which such Purchaser agreed
to purchase hereunder) of the Securities of such defaulting Purchaser or
Purchasers for which such arrangements have not been made; but nothing herein
shall relieve a defaulting Purchaser from liability for its default.

        (c) If, after giving effect to any arrangements for the purchase of the
Securities of a defaulting Purchaser or Purchasers by you and the Company as
provided in subsection (a) above, the aggregate principal amount of Securities
which remains unpurchased exceeds one-eleventh of the aggregate principal amount
of all the Securities, or if the Company shall not exercise the right described
in subsection (b) above to require non-defaulting Purchasers to purchase
Securities of a defaulting Purchaser or Purchasers, then this Agreement shall
thereupon terminate, without liability on the part of any non-defaulting
Purchaser or the Company, except for the expenses to be borne by the Company and
the Purchasers as provided in Section 6 hereof and the indemnity and
contribution agreements in Section 8 hereof; but nothing herein shall relieve a
defaulting Purchaser from liability for its default.

                                       19
<PAGE>   20

        10. The respective indemnities, agreements, representations, warranties
and other statements of the Company and the several Purchasers, as set forth in
this Agreement or made by or on behalf of them, respectively, pursuant to this
Agreement, shall remain in full force and effect, regardless of any
investigation (or any statement as to the results thereof) made by or on behalf
of any Purchaser or any controlling person of any Purchaser, or the Company, or
any officer or director or controlling person of the Company, and shall survive
delivery of and payment for the Securities.

        11. If this Agreement shall be terminated pursuant to Section 9 hereof,
the Company shall not then be under any liability to any Purchaser except as
provided in Sections 6 and 8 hereof; but, if for any other reason, the
Securities are not delivered by or on behalf of the Company as provided herein,
the Company will reimburse the Purchasers through you for all out-of-pocket
expenses approved in writing by you, including fees and disbursements of
counsel, reasonably incurred by the Purchasers in making preparations for the
purchase, sale and delivery of the Securities, but the Company shall then be
under no further liability to any Purchaser except as provided in Sections 6 and
8 hereof.

        12. In all dealings hereunder, you shall act on behalf of each of the
Purchasers, and the parties hereto shall be entitled to act and rely upon any
statement, request, notice or agreement on behalf of any Purchaser made or given
by you jointly or by Goldman, Sachs & Co. on behalf of you as the
Representatives.

        All statements, requests, notices and agreements hereunder shall be in
writing, and if to the Purchasers shall be delivered or sent by mail, telex or
facsimile transmission to you as the Representatives in care of Goldman, Sachs &
Co., 32 Old Slip, 21st Floor, New York, New York 10005, Attention: Registration
Department; and if to the Company shall be delivered or sent by mail, telex or
facsimile transmission to the address of the Company set forth in the Offering
Circular, Attention: General Counsel; provided, however, that any notice to a
Purchaser pursuant to Section 8(c) hereof shall be delivered or sent by mail,
telex or facsimile transmission to such Purchaser at its address set forth in
its Purchasers' Questionnaire, or telex constituting such Questionnaire, which
address will be supplied to the Company by you upon request. Any such
statements, requests, notices or agreements shall take effect upon receipt
thereof.

        13. This Agreement shall be binding upon, and inure solely to the
benefit of, the Purchasers, the Company and, to the extent provided in Sections
8 and 10 hereof, the officers and directors of the Company and each person who
controls the Company or any Purchaser, and their respective heirs, executors,
administrators, successors and assigns, and no other person shall acquire or
have any right under or by virtue of this Agreement. No purchaser of any of the
Securities from any Purchaser shall be deemed a successor or assign by reason
merely of such purchase.

        14. Time shall be of the essence of this Agreement.

                                       20
<PAGE>   21

        15. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH
THE LAWS OF THE STATE OF NEW YORK.

        16. This Agreement may be executed by any one or more of the parties
hereto in any number of counterparts, each of which shall be deemed to be an
original, but all such respective counterparts shall together constitute one and
the same instrument.

        If the foregoing is in accordance with your understanding, please sign
and return to us six counterparts hereof, and upon the acceptance hereof by you,
on behalf of each of the Purchasers, this letter and such acceptance hereof
shall constitute a binding agreement between each of the Purchasers and the
Company. It is understood that your acceptance of this letter on behalf of each
of the Purchasers is pursuant to the authority set forth in a form of Agreement
among Purchasers, the form of which shall be submitted to the Company for
examination upon request, but without warranty on your part as to the authority
of the signers thereof.

                                        Very truly yours,

                                        COR THERAPEUTICS, INC.

                                        By: /s/ PETER S. RODDY
                                           ------------------------------------
                                           Name:  Peter S. Roddy
                                           Title: Vice President, Finance

Accepted as of the date hereof:

Goldman, Sachs & Co.,
Chase H&Q, A Division of Chase Securities Inc.,
CIBC World Markets Corp.,
FleetBoston Robertson Stephens Inc.,
Warburg Dillon Read LLC

By: /s/ GOLDMAN, SACHS & CO.
   --------------------------------------------------------
                    (Goldman, Sachs & Co.)

             On behalf of each of the Purchasers

                                       21
<PAGE>   22

                                   SCHEDULE I
<TABLE>
<CAPTION>
                                                                                       PRINCIPAL AMOUNT OF
                                                                                       OPTIONAL SECURITIES
                                                               PRINCIPAL AMOUNT OF     TO BE PURCHASED IF
                                                                FIRM SECURITIES TO        MAXIMUM OPTION
                       PURCHASER                                   BE PURCHASED             EXERCISED
<S>                                                            <C>                     <C>
Goldman, Sachs & Co........................................         $150,000,000       $   30,000,000
Chase H&Q, A Division of Chase Securities Inc. ............           25,000,000            5,000,000
CIBC World Markets Corp. ..................................           25,000,000            5,000,000
FleetBoston Robertson Stephens, Inc. ......................           27,500,000            5,500,000
Warburg Dillon Read LLC  ..................................           22,500,000            4,500,000

                  Total....................................         $250,000,000       $   50,000,000
</TABLE>

<PAGE>   23

                                                                         ANNEX I

        Pursuant to Section 7(c) of the Purchase Agreement, the accountants
shall furnish letters to the Purchasers to the effect that:

               (i) They are independent certified public accountants with
        respect to the Company and its subsidiaries within the meaning of the
        Securities Exchange Act of 1934 (the "Exchange Act") and the applicable
        published rules and regulations thereunder;

               (ii) In their opinion, the consolidated financial statements and
        financial statement schedules audited by them and included in the
        Offering Circular comply as to form in all material respects with the
        applicable requirements of the Exchange Act and the related published
        rules and regulations;

               (iii) The unaudited selected financial information with respect
        to the consolidated results of operations and financial position of the
        Company for the five most recent fiscal years included in the Offering
        Circular agrees with the corresponding amounts (after restatements where
        applicable) in the audited consolidated financial statements for such
        five fiscal years;

               (iv) On the basis of limited procedures not constituting an audit
        in accordance with generally accepted auditing standards, consisting of
        a reading of the unaudited financial statements and other information
        referred to below, a reading of the latest available interim financial
        statements of the Company and its subsidiaries, inspection of the minute
        books of the Company and its subsidiaries since the date of the latest
        audited financial statements included in the Offering Circular,
        inquiries of officials of the Company and its subsidiaries responsible
        for financial and accounting matters and such other inquiries and
        procedures as may be specified in such letter, nothing came to their
        attention that caused them to believe that:

                   (A) the unaudited consolidated statements of income,
               consolidated balance sheets and consolidated statements of cash
               flows included in the Offering Circular are not in conformity
               with generally accepted accounting principles applied on the
               basis substantially consistent with the basis for the unaudited
               condensed consolidated statements of income, consolidated balance
               sheets and consolidated statements of cash flows included in the
               Offering Circular;

                   (B) any other unaudited income statement data and balance
               sheet items included in the Offering Circular do not agree with
               the corresponding items in the unaudited consolidated financial
               statements from which such data and items were derived, and any
               such unaudited data and items were not determined on a basis
               substantially consistent with the basis for the corresponding
               amounts in the audited consolidated financial statements included
               in the Offering Circular;

                   (C) the unaudited financial statements which were not
               included in the Offering Circular but from which were derived any
               unaudited condensed financial statements

<PAGE>   24

               referred to in clause (A) and any unaudited income statement data
               and balance sheet items included in the Offering Circular and
               referred to in clause (B) were not determined on a basis
               substantially consistent with the basis for the audited
               consolidated financial statements included in the Offering
               Circular;

                   (D) any unaudited pro forma consolidated condensed financial
               statements included in the Offering Circular do not comply as to
               form in all material respects with the applicable accounting
               requirements or the pro forma adjustments have not been properly
               applied to the historical amounts in the compilation of those
               statements;

                   (E) as of a specified date not more than five days prior to
               the date of such letter, there have been any changes in the
               consolidated capital stock (other than issuances of capital stock
               upon exercise of options and stock appreciation rights and
               pursuant to the Company's employee stock purchase plan, upon
               earn-outs of performance shares and upon conversions of
               convertible securities, in each case which were outstanding on
               the date of the latest financial statements included in the
               Offering Circular) or any increase in the consolidated long-term
               debt of the Company and its subsidiaries, or any decreases in
               consolidated net current assets or stockholders' equity or other
               items specified by the Representatives, or any increases in any
               items specified by the Representatives, in each case as compared
               with amounts shown in the latest balance sheet included in the
               Offering Circular except in each case for changes, increases or
               decreases which the Offering Circular discloses have occurred or
               may occur or which are described in such letter; and

                   (F) for the period from the date of the latest financial
               statements included in the Offering Circular to the specified
               date referred to in clause (E) there were any decreases in
               consolidated net revenues or operating profit or the total or per
               share amounts of consolidated net income or other items specified
               by the Representatives, or any increases in any items specified
               by the Representatives, in each case as compared with the
               comparable period of the preceding year and with any other period
               of corresponding length specified by the Representatives, except
               in each case for decreases or increases which the Offering
               Circular discloses have occurred or may occur or which are
               described in such letter; and

               (v) In addition to the examination referred to in their report(s)
        included in the Offering Circular and the limited procedures, inspection
        of minute books, inquiries and other procedures referred to in
        paragraphs (iii) and (iv) above, they have carried out certain specified
        procedures, not constituting an audit in accordance with generally
        accepted auditing standards, with respect to certain amounts,
        percentages and financial information specified by the Representatives,
        which are derived from the general accounting records of the Company and
        its subsidiaries, which appear in the Offering Circular, and have
        compared certain of such amounts, percentages and financial information
        with the accounting records of the Company and its subsidiaries and have
        found them to be in agreement.

                                      I-2
<PAGE>   25

                                    EXHIBIT A

                          REGISTRATION RIGHTS AGREEMENT

                                       A-1
<PAGE>   26

                                    EXHIBIT B

                             COR THERAPEUTICS, INC.

                                LOCK-UP AGREEMENT

                          DATED AS OF FEBRUARY 15, 2000

Goldman, Sachs & Co.,
Chase H&Q, A Division of Chase Securities Inc.,
CIBC World Markets Corp.,
FleetBoston Robertson Stephens Inc.,
Warburg Dillon Read LLC,
c/o Goldman, Sachs & Co.,
85 Broad Street,
New York, NY 10004.

        Re: COR Therapeutics, Inc. - Lock-Up Agreement

Ladies and Gentlemen:

        The undersigned understands that you, as representatives (the
"Representatives"), propose to enter into a Purchase Agreement on behalf of the
several Purchasers named in Schedule I to such agreement (collectively, the
"Purchasers"), with COR Therapeutics, Inc., a Delaware corporation (the
"Company"), providing for an offering of Convertible Subordinated Notes (the
"Notes") of the Company that will be convertible into shares of the Common Stock
of the Company (the "Common Stock").

        In consideration of the agreement by the Purchasers to offer and sell
the Notes, and of other good and valuable consideration the receipt and
sufficiency of which are hereby acknowledged, the undersigned agrees that,
during the period beginning from the date of the final Offering Circular
covering the offering of the Notes and continuing to and including the date 90
days after the date of such final Offering Circular (the "Lock-Up Period"), the
undersigned will not offer, sell, contract to sell, pledge, grant any option to
purchase, make any short sale or otherwise dispose of, or exercise any
registration rights with respect to, any shares of Common Stock of the Company,
or any options or warrants to purchase any shares of Common Stock of the
Company, or any securities convertible into, exchangeable for or that represent
the right to receive shares of Common Stock of the Company, whether now owned or
hereinafter acquired, owned directly by the undersigned (including holding as a
custodian) or with respect to which the undersigned has beneficial ownership
within the rules and regulations of the Securities and Exchange Commission (the
"SEC") (collectively the "Undersigned's Shares").

                                      B-1
<PAGE>   27

        The foregoing restriction is expressly agreed to preclude the
undersigned from engaging in any hedging or other transaction which is designed
to or which reasonably could be expected to lead to or result in a sale or
disposition of the Undersigned's Shares even if such Shares would be disposed of
by someone other than the undersigned. Such prohibited hedging or other
transactions would include without limitation any short sale or any purchase,
sale or grant of any right (including without limitation any put or call option)
with respect to any of the Undersigned's Shares or with respect to any security
that includes, relates to, or derives any significant part of its value from
such Shares.

        Notwithstanding the foregoing, the undersigned may transfer the
Undersigned's Shares (i) as a bona fide gift or gifts, provided that the donee
or donees thereof agree to be bound in writing by the restrictions set forth
herein, (ii) to any trust for the direct or indirect benefit of the undersigned
or the immediate family of the undersigned, provided that the trustee of the
trust agrees to be bound in writing by the restrictions set forth herein, and
provided further that any such transfer shall not involve a disposition for
value, (iii) with the prior written consent of Goldman, Sachs & Co. on behalf of
the Purchasers or, (iv) after the first 60 days of the Lock-Up Period, the
undersigned may transfer up to ten percent (10%) of the Undersigned's Shares
without any restrictions pursuant to this Lock-Up Agreement. For purposes of
this Lock-Up Agreement, "immediate family" shall mean any relationship by blood,
marriage or adoption, not more remote than first cousin. The undersigned now
has, and, except as contemplated by clause (i), (ii), (iii) or (iv) above, for
the duration of this Lock-Up Agreement will have, good and marketable title to
the Undersigned's Shares, free and clear of all liens, encumbrances, and claims
whatsoever. The undersigned also agrees and consents to the entry of stop
transfer instructions with the Company's transfer agent and registrar against
the transfer of the Undersigned's Shares except in compliance with the foregoing
restrictions.

        The undersigned understands that the Company and the Purchasers are
relying upon this Lock-Up Agreement in proceeding toward consummation of the
offering. The undersigned further understands that this Lock-Up Agreement is
irrevocable and shall be binding upon the undersigned's heirs, legal
representatives, successors, and assigns.

                                        Very truly yours,

                                        ----------------------------------------

                                        Exact Name of Shareholder

                                        ----------------------------------------

                                        Authorized Signature

                                        ----------------------------------------

                                        Title

                                       B-2
<PAGE>   28

                                   EXHIBIT B-1

List of person to sign
Lock-Up Agreements:

VAUGHN M. KAILIAN
CHARLES J. HOMCY
SHAUN R. COUGHLIN
JAMES T. DOLUISIO
JERRY T. JACKSON
ERNEST MARIO
ROBERT MOMSEN
LLOYD HOLLINGSWORTH SMITH JR.
MARK PERRIN
LEE RAUCH
PATRICK BRODERICK

                                      B-3<PAGE>   1

                                                                    EXHIBIT 10.2

                             COR THERAPEUTICS, INC.
             5.00% CONVERTIBLE SUBORDINATED NOTES DUE MARCH 1, 2007

                          REGISTRATION RIGHTS AGREEMENT

                                                               February 24, 2000

Goldman, Sachs & Co.,
Chase H&Q, A Division of Chase Securities Inc.,
CIBC World Markets Corp.,
FleetBoston Robertson Stephens Inc.,
Warburg Dillon Read LLC,
c/o Goldman, Sachs & Co.,
85 Broad Street,
New York, New York  10004.

Ladies and Gentlemen:

        COR Therapeutics, Inc., a Delaware corporation (the "Company"), proposes
to issue and sell to you (the "Purchasers") upon the terms set forth in a
purchase agreement dated February 17, 2000 (the "Purchase Agreement"), between
the Purchasers and the Company, its 5.00% Convertible Subordinated Notes due
March 1, 2007 (the "Securities"). As an inducement to the Purchasers to enter
into the Purchase Agreement and in satisfaction of a condition to the
obligations of the Purchasers thereunder, the Company agrees with the
Purchasers, (i) for the benefit of the Purchasers and (ii) for the benefit of
the Holders (as defined below) from time to time of the Registrable Securities
(as defined below), including the Purchasers, as follows:

        1. Definitions. Capitalized terms used herein without definition shall
have the meanings ascribed to them in the Purchase Agreement or the Offering
Circular, each dated February 17, 2000, in respect of the Securities. As used in
this Agreement, the following capitalized defined terms shall have the following
meanings:

        "Act" or "Securities Act" means the United States Securities Act of
1933, as amended.

                                       1
<PAGE>   2

        "Affiliate" of any specified person means any other person which,
directly or indirectly, is in control of, is controlled by, or is under common
control with such specified person. For purposes of this definition, "control"
of a person means the power, direct or indirect, to direct or cause the
direction of the management and policies of such person whether by contract or
otherwise; and the terms "controlling" and "controlled" have meanings
correlative to the foregoing.

        "Closing Date" means the First Time of Delivery as defined in the
Purchase Agreement.

        "Commission" means the United States Securities and Exchange Commission.

        "Common Stock" means the common stock, par value $0.0001 per share, of
the Company, and any securities of the Company or any successor which may be
issuable upon conversion of the Securities pursuant to Article Eleven of the
Indenture.

        "DTC" means The Depository Trust Company.

        "Effectiveness Period" has the meaning set forth in Section 2(b) hereof.

        "Electing Holder" means any Holder of Registrable Securities that has
returned a properly completed and signed Notice and Questionnaire to the Company
in accordance with Section 3(b) hereof.

        "Exchange Act" means the United States Securities Exchange Act of 1934,
as amended.

        "Holder" means any person that is the record owner of Registrable
Securities (and includes any person that has a beneficial interest in any
Registrable Security in book-entry form).

        "Indenture" means the Indenture, dated as of February 24, 2000, between
the Company and Firstar Bank, N.A., as Trustee, as amended and supplemented from
time to time in accordance with its terms.

        "Managing Underwriters" means the investment banker or investment
bankers and manager or managers that shall administer an underwritten offering,
if any, as set forth in Section 6 hereof.

        "Person" means an individual, partnership, corporation, limited
liability company, trust or unincorporated organization, or a government or
agency or political subdivision thereof.

        "Prospectus" means the prospectus included in any Shelf Registration
Statement (including, without limitation, a prospectus that discloses
information previously omitted from a prospectus filed as part of an effective
registration statement in reliance upon Rule 430A under the Act), as amended or
supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities.

        "Registrable Security" means any Security and any share of Common Stock
issuable upon conversion or repurchase thereof except any such Security or share
of Common Stock which (i) has been effectively registered under the Securities
Act and sold in a manner contemplated by the Shelf

                                       2
<PAGE>   3

Registration Statement, (ii) has been transferred in compliance with Rule 144
under the Securities Act (or any successor provision thereto) or is transferable
pursuant to paragraph (k) of such Rule 144 (or any successor provision thereto)
("Rule 144(k)"), or (iii) has otherwise been transferred and a new Security or
share of Common Stock not subject to transfer restrictions under the Securities
Act has been delivered by or on behalf of the Company in accordance with Section
3.5(b) of the Indenture.

        "Shelf Registration" means a registration effected pursuant to Section 2
hereof.

        "Shelf Registration Statement" means a shelf registration statement of
the Company pursuant to the provisions of Section 2 hereof filed with the
Commission which covers some or all of the Registrable Securities, as
applicable, on an appropriate form under Rule 415 under the Act, or any similar
rule that may be adopted by the Commission, amendments and supplements to such
registration statement, including post-effective amendments, in each case
including the Prospectus contained therein, all exhibits thereto and all
material incorporated by reference therein.

        "Underwriter" means any underwriter of Registrable Securities in
connection with an offering thereof under a Shelf Registration Statement.

        2. Shelf Registration.

        (a) The Company shall, no later than 90 calendar days following the
Closing Date, file with the Commission a Shelf Registration Statement relating
to the offer and sale of the Registrable Securities by the Holders from time to
time in accordance with the methods of distribution elected by such Holders and
set forth in such Shelf Registration Statement and, thereafter, shall use its
reasonable efforts to cause such Shelf Registration Statement to be declared
effective under the Act within 180 calendar days following the Closing Date;
provided, however, that the Company may, upon written notice to all the Holders,
postpone having the Shelf Registration Statement declared effective for a
reasonable period not to exceed 90 days if the Company possesses material
non-public information, the disclosure of which would have a material adverse
effect on the Company and its subsidiaries taken as a whole; provided, further,
however, that no Holder shall be entitled to have the Registrable Securities
held by it covered by such Shelf Registration unless such Holder is an Electing
Holder.

        (b) The Company shall use its reasonable efforts:

              (i) To keep the Shelf Registration Statement continuously
        effective in order to permit the Prospectus forming part thereof to be
        usable by Holders until the earliest of (1) the sale of all Registrable
        Securities registered under the Shelf Registration Statement; (2) the
        expiration of the period referred to in Rule 144(k) with respect to all
        Registrable Securities held by Persons that are not Affiliates of the
        Company; and (3) two years from the date (the "Effective Date") such
        Shelf Registration Statement is declared effective (such period being
        called the "Effectiveness Period"); and

                                       3
<PAGE>   4

              (ii) After the Shelf Registration Statement is declared effective
        by the Commission, upon the request of an Electing Holder, to take
        action reasonably necessary to register the sale of any Registrable
        Securities of such Electing Holder and to identify such Electing Holder
        as a selling securityholder.

The Company shall be deemed not to have used its reasonable efforts to keep the
Shelf Registration Statement effective during the requisite period if the
Company voluntarily takes any action that would result in Holders of Registrable
Securities covered thereby not being able to offer and sell any such Registrable
Securities during that period, unless such action is required by applicable law
and the Company thereafter promptly complies with the requirements of paragraph
3(k) below.

        (c) The Company may suspend the use of the Prospectus for a period not
to exceed 45 days in any 90-day period or an aggregate of 90 days in any 365-day
period if the Board of Directors of the Company shall have determined in good
faith that because of valid business reasons (not including avoidance of the
Company's obligations hereunder), including the acquisition or divestiture of
assets, pending corporate developments and similar events, it is in the best
interests of the Company to suspend such use, and prior to suspending such use
the Company provides the Holders with written notice of such suspension, which
notice need not specify the nature of the event giving rise to such suspension.

        (d) Without limiting the remedies available to the Electing Holders
under Section 7 hereof, the Company acknowledges that any failure by the Company
to comply with its obligations under Section 2(a) hereof may result in material
irreparable injury to the Purchasers or the Electing Holders for which there is
no adequate remedy at law, that it will not be possible to measure damages for
such injuries precisely and that, in the event of any such failure, the
Purchasers or any Electing Holder may obtain such relief as may be required to
specifically enforce the Company's obligations under Section 2(a) hereof.

        3. Registration Procedures. In connection with any Shelf Registration
Statement, the following provisions shall apply:

        (a) The Company shall prepare and file with the Commission the Shelf
Registration Statement on the appropriate form under the Act (x) which form
shall be selected by the Company, (y) which form shall be available for the sale
of the Registrable Securities by the Electing Holders and (z) which Shelf
Registration Statement and any amendment thereto and the Prospectus forming part
thereof and any amendment or supplement thereto (and each other document
incorporated therein by reference in each case) shall comply as to form in all
material respects with the Act and the Exchange Act and the respective rules and
regulations thereunder and shall include (or incorporate by reference) all
financial statements required by the Commission to be filed therewith, and shall
use its reasonable efforts to cause such Shelf Registration Statement to become
effective and remain effective in accordance with Section 2 hereof.

                                       4
<PAGE>   5

              (b) (1) The Company shall mail the Notice and Questionnaire to the
        Holders of Registrable Securities not less than 30 calendar days prior
        to the time the Company intends in good faith to have the Shelf
        Registration Statement declared effective. Any Person that acquires any
        Registrable Securities from an Electing Holder in compliance with the
        applicable provisions of the Securities (excluding any Registrable
        Securities that were not identified in the Notice and Questionnaire
        delivered by such Electing Holder) will be entitled to have such
        Registrable Securities included in the Shelf Registration Statement so
        long as such transferee provides the Company with an updated Notice and
        Questionnaire prior to the Questionnaire Deadline (as defined below).
        Subject to Section 3(b)(2) hereof, no Holder of Registrable Securities
        shall be entitled to be named as a selling securityholder in the Shelf
        Registration Statement as of the Effective Date, and no Holder of
        Registrable Securities shall be entitled to use the Prospectus forming a
        part thereof for offers and resales of Registrable Securities at any
        time, unless such Holder has returned a completed and signed Notice and
        Questionnaire to the Company by the deadline for response set forth
        therein (the "Questionnaire Deadline"), such response deadline to be on
        a date not less than 30 calendar days after the date of mailing of the
        Notice and Questionnaire by the Company.

              (2) After the Effective Date of the Shelf Registration Statement,
        the Company shall, upon the request of any Holder of Registrable
        Securities that is not then an Electing Holder, as promptly as
        reasonably practicable, send a Notice and Questionnaire to such Holder.
        The Company shall not be required to take any action to name such Holder
        as a selling securityholder in the Shelf Registration Statement until
        such Holder has returned a completed and signed Notice and Questionnaire
        to the Company. Following its receipt of such Notice and Questionnaire,
        the Company will reasonably promptly include the Registrable Securities
        covered thereby in the Shelf Registration Statement (if not previously
        included).

              (3) If such complete Notice and Questionnaire is received by the
        Company before 10 days prior to the Effective Date, such Holder shall be
        entitled to have its Registrable Securities included in the Shelf
        Registration Statement at the Effective Date. If the Company receives
        such complete Notice and Questionnaire after the 10th day prior to the
        Effective Date, the Registrable Securities covered by the Notice and
        Questionnaire will be included in the Shelf Registration Statement as
        promptly as reasonably practicable after receipt of such Notice and
        Questionnaire.

              (4) In the event that the Company receives such complete Notice
        and Questionnaire after the Shelf Registration Statement has been
        declared effective, the Company will, as promptly as reasonably
        practicable following receipt of the complete Notice and Questionnaire,
        file any amendments to the Shelf Registration Statement or supplements
        related to the Prospectus as are necessary to permit such Holder to
        deliver the Prospectus to purchasers of the Registrable Securities. The
        Company shall use reasonable efforts to cause such post-effective
        amendment to the Shelf Registration Statement to be declared effective
        within 45 days of the filing of such post-effective amendment. The
        Company may take reasonable steps to aggregate the addition of
        Registrable Securities of more than one

                                       5
<PAGE>   6

        Holder for purposes of filing amendments to the Shelf Registration
        Statement or supplements to the Prospectus so as to reduce the need for
        multiple amendments or supplements, but the Company shall not utilize
        this provision to delay any filing requested by any of the Purchasers.

        (c) The Company shall furnish to the Holders, prior to the filing
thereof with the Commission, a copy of any Shelf Registration Statement, and
each amendment thereof and each amendment or supplement, if any, to the
Prospectus included therein and shall use reasonable efforts to reflect in each
such document, when so filed with the Commission, such comments as the Holders
reasonably may propose.

        (d) The Company shall take such action as may be necessary so that (i)
any Shelf Registration Statement and any amendment thereto and any Prospectus
forming part thereof and any amendment or supplement thereto (and each report or
other document incorporated therein by reference in each case) complies in all
material respects with the Securities Act and the Exchange Act and the
respective rules and regulations thereunder, (ii) any Shelf Registration
Statement and any amendment thereto does not, when it becomes effective, contain
an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading
and (iii) any Prospectus forming part of any Shelf Registration Statement, and
any amendment or supplement to such Prospectus, does not include an untrue
statement of a material fact or omit to state a material fact necessary in order
to make the statements, in the light of the circumstances under which they were
made, not misleading.

        (e) (i) The Company shall advise the Purchasers, the Electing Holders
        and the Managing Underwriter or Underwriters promptly and, if requested
        by the Purchasers or any Electing Holder, confirm such advice in
        writing:

                    (1) when a Shelf Registration Statement and any amendment
              thereto has been filed with the Commission and when the Shelf
              Registration Statement or any post-effective amendment thereto has
              become effective in each case making a public announcement thereof
              by release made to Reuters Economic Services and Bloomberg
              Business News;

                    (2) when the Company receives any request by the Commission
              for amendments or supplements to the Shelf Registration Statement
              or the Prospectus included therein or for additional information;

                    (3) when the Commission issues any stop order suspending
              effectiveness of the Shelf Registration Statement or initiates any
              proceedings for that purpose;

                    (4) when the Company receives any notification with respect
              to the suspension of the qualification of the securities included
              therein for sale in any jurisdiction or the initiation of any
              proceeding for such purpose; and

                                       6
<PAGE>   7

              (ii) The Company shall, as promptly as reasonably practicable,
        advise the Purchasers, the Electing Holders and each Managing
        Underwriter, if any, of the happening of any event that requires the
        making of any changes to the Shelf Registration Statement or the
        Prospectus so that, as of such date, the Shelf Registration Statement
        and the Prospectus do not contain an untrue statement of a material fact
        and do not omit to state a material fact required to be stated therein
        or necessary to make the statements therein (in the case of the
        Prospectus, in light of the circumstances under which they were made)
        not misleading (which advice shall be accompanied by an instruction to
        suspend the use of the Prospectus until the requisite changes have been
        made).

        (f) The Company shall use reasonable efforts to prevent the issuance,
and if issued to obtain the withdrawal, of any order suspending the
effectiveness of any Shelf Registration Statement at the earliest possible time.

        (g) The Company shall furnish to each Electing Holder, counsel for the
Purchasers, each Purchaser and each Managing Underwriter, if any, with respect
to a Shelf Registration Statement, without charge, at least one copy of such
Shelf Registration Statement and any post-effective amendment thereto, including
financial statements and schedules, and, if the Electing Holder so requests in
writing, all exhibits (including those incorporated by reference).

        (h) The Company shall, during the Effectiveness Period, deliver to each
Electing Holder and each Managing Underwriter, if any, with respect to a Shelf
Registration Statement, without charge, as many copies of the Prospectus
(including each preliminary Prospectus) included in such Shelf Registration
Statement and any amendment or supplement thereto as such Electing Holder may
reasonably request; and the Company consents (except during the continuance of
any event described in Section 3(e)(ii)) to the use of the Prospectus or any
amendment or supplement thereto by each of the Electing Holders in connection
with the offering and sale of the Registrable Securities covered by the
Prospectus and any amendment or supplement thereto during the Effectiveness
Period.

        (i) Prior to any offering of Registrable Securities pursuant to any
Shelf Registration Statement, the Company shall register or qualify or cooperate
with the Purchasers and their counsel in connection with the registration or
qualification of such Registrable Securities for offer and sale under the
securities or blue sky laws of such jurisdictions as any such Electing Holders
reasonably request in writing and do any and all other acts or things necessary
or advisable to enable the offer and sale in such jurisdictions of the
Registrable Securities covered by such Shelf Registration Statement; provided,
however, that in no event shall the Company be obligated to (i) qualify as a
foreign corporation or as a dealer in securities in any jurisdiction where it
would not otherwise be required to so qualify but for this Section 3(i), (ii)
file any general consent to service of process or taxation in any jurisdiction
where it is not as of the date hereof then so subject or (iii) subject itself to
taxation in any jurisdiction if it is not so subject.

                                       7
<PAGE>   8

        (j) Unless any Registrable Securities shall be in book-entry only form,
the Company shall cooperate with the Electing Holders to facilitate the timely
preparation and delivery of certificates representing Registrable Securities to
be sold pursuant to any Shelf Registration Statement free of any restrictive
legends and in such permitted denominations and registered in such names as
Electing Holders may request in connection with the sale of Registrable
Securities pursuant to such Shelf Registration Statement.

        (k) Upon the occurrence of any event contemplated by paragraph 3(e)(ii)
above, the Company shall promptly prepare a post-effective amendment to any
Shelf Registration Statement or an amendment or supplement to the related
Prospectus or file any other required document so that, as thereafter delivered
to purchasers of the Registrable Securities included therein, the Prospectus
will not include an untrue statement of a material fact or omit to state any
material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading. If the Company
notifies the Electing Holders of the occurrence of any event contemplated by
paragraph 3(e)(ii) above, the Electing Holders shall suspend the use of the
Prospectus until the requisite changes to the Prospectus have been made.

        (l) Not later than the effective date of any Shelf Registration
Statement hereunder, the Company shall provide a CUSIP number for the Securities
registered under such Shelf Registration Statement.

        (m) The Company shall use reasonable efforts to comply with all
applicable rules and regulations of the Commission and shall make generally
available to their security holders or otherwise provide in accordance with
Section 11(a) of the Securities Act as soon as practicable after the effective
date of the applicable Shelf Registration Statement an earnings statement
satisfying the provisions of Section 11(a) of the Securities Act.

        (n) The Company shall cause the Indenture and the Securities to be
qualified under the Trust Indenture Act in a timely manner; and in connection
with such qualification, the Company shall cooperate with the Trustee under the
Indenture and the Holders (as defined in the Indenture) to effect such changes
to the Indenture as may be required for such Indenture to be so qualified in
accordance with the terms of the Trust Indenture Act; and the Company shall
execute and use all reasonable efforts to cause the Trustee to execute, all
documents that may be required to effect such changes and all other forms and
documents required to be filed with the Commission to enable such Indenture to
be so qualified in a timely manner.

        (o) In the event of an underwritten offering as set forth in Section 6
herein, the Company shall, if requested, promptly include or incorporate in a
Prospectus supplement or post-effective amendment to a Shelf Registration
Statement, such information as the Managing Underwriter or Underwriters
reasonably request to be included therein and to which the Company does not
reasonably object and shall make all required filings of such Prospectus
supplement or post-effective amendment as soon as practicable after it is
notified of the matters to be included or incorporated in such Prospectus
supplement or post-effective amendment.

                                       8
<PAGE>   9

           (p) The Company shall enter into such customary agreements (including
underwriting agreements in customary form) to take all other appropriate actions
in order to expedite or facilitate the registration or the disposition of the
Registrable Securities, and in connection therewith, if an underwriting
agreement is entered into, cause the same to contain indemnification provisions
and procedures substantially identical to those set forth in Section 5 (or such
other provisions and procedures acceptable to the Managing Underwriters, if any)
with respect to all parties to be indemnified pursuant to Section 5.

        (q) The Company shall:

              (i) make reasonably available for inspection by one or more
        representative of the Electing Holders designated in writing by the
        Holders of a majority of the Registrable Securities to be registered
        thereunder, any Underwriter participating in any disposition pursuant to
        such Shelf Registration Statement, and any attorney, accountant or other
        agent retained by such representative or any such Underwriter all
        relevant financial and other records, pertinent corporate documents and
        properties of the Company and its subsidiaries;

              (ii) cause the Company's officers, directors and employees to make
        reasonably available for inspection all relevant information reasonably
        requested by such representative or any such Underwriter, attorney,
        accountant or agent in connection with any such Shelf Registration
        Statement, in each case, as is customary for similar due diligence
        examinations; provided, however, that any information that is designated
        in writing by the Company, in good faith, as confidential at the time of
        delivery of such information shall be kept confidential by such
        representative, any Holders or any such Underwriter, attorney,
        accountant or agent, unless such disclosure is made in connection with a
        court proceeding or required by law, or such information becomes
        available to the public generally or through a third party without an
        accompanying obligation of confidentiality;

              (iii) make such representations and warranties to the Electing
        Holders and the Underwriters, if any, in form, substance and scope as
        are customarily made by the Company to underwriters in primary
        underwritten offerings and covering matters including, but not limited
        to, those set forth in the Purchase Agreement;

              (iv) use its reasonable efforts to obtain opinions of counsel to
        the Company and updates thereof (which counsel and opinions (in form,
        scope and substance) shall be reasonably satisfactory to the Managing
        Underwriters, if any) addressed to each Electing Holder and the
        Underwriters, if any, covering such matters as are customarily covered
        in opinions requested in underwritten offerings and such other matters
        as may be reasonably requested by such Electing Holders and Underwriters
        (it being agreed that the matters to be covered by such opinion or
        written statement by such counsel delivered in connection with such
        opinions shall include in customary form, without limitation, as of the
        date of the opinion and as of the effective date of the Shelf
        Registration Statement or most recent post-effective amendment thereto,
        as the case may be, the absence from such Shelf Registration Statement
        and the prospectus included therein, as then amended or supplemented,
        including the documents incorporated by reference therein, of an untrue
        statement of a

                                       9
<PAGE>   10

        material fact or the omission to state therein a material fact required
        to be stated therein or necessary to make the statements therein not
        misleading);

              (v) use its reasonable efforts to obtain "cold comfort" letters
        and updates thereof from the independent public accountants of the
        Company (and, if necessary, any other independent public accountants of
        any subsidiary of the Company or of any business acquired by the Company
        for which financial statements and financial data are, or are required
        to be, included in the Shelf Registration Statement), addressed to each
        Electing Holder and the Underwriters, if any, in customary form and
        covering matters of the type customarily covered in "cold comfort"
        letters in connection with primary underwritten offerings;

              (vi) deliver such documents and certificates as may be reasonably
        requested by any such Electing Holders and the Managing Underwriters, if
        any, including those to evidence compliance with Section 3(d) and with
        any customary conditions contained in the underwriting agreement or
        other agreement entered into by the Company.

        The foregoing actions set forth in clauses (iii), (iv), (v) and (vi) of
        this Section 3(p) shall be performed at each closing under any
        underwritten offering to the extent required thereunder (including at
        any closing relating to the exercise by underwriters of their
        over-allotment options, if any).

        (r) The Company will use its reasonable efforts to cause the Stock
issuable upon conversion of the Securities to be admitted for quotation on the
Nasdaq National Market or other stock exchange or trading system on which the
Stock primarily trades on or prior to the effective date of any Shelf
Registration Statement hereunder.

        (s) In the event that any broker-dealer registered under the Exchange
Act shall be an "Affiliate" (as defined in Rule 2720(b)(i) of the Rules of
Conduct of the National Association of Securities Dealers, Inc. (the "NASD") (or
any successor or analogous provision thereto)) of the Company or has a "Conflict
of Interest" (as defined in Rule 2720(b)(7) of the Rules of Conduct of the NASD
(or any successor an analogous provision thereto)) and such broker-dealer shall
underwrite, participate as a member of an underwriting syndicate or selling
group or "assist in the distribution" (within the meaning of such rule) of any
Registrable Securities, whether as a holder of such Registrable Securities or as
an underwriter, a placement or sales agent or a broker or dealer in respect
thereof, or otherwise, assist such broker-dealer (at the expense of such
broker-dealer) in complying with the requirements of such rule, including,
without limitation, by (A) engaging a "qualified independent underwriter" (as
defined in such rule) to participate in the preparation of the registration
statement relating to such Registrable Securities, to exercise usual standards
of due diligence in respect thereto and to recommend the public offering price
of such Registrable Securities, (B) indemnifying such qualified independent
underwriter to the extent of the indemnification of Underwriters provided in
Section 5 hereof, and (C) providing such information to such broker-dealer as
may be required in order for such broker-dealer to comply with the requirements
of the Rules of Conduct of the NASD.

                                       10
<PAGE>   11

        (t) The Company shall use reasonable efforts to take all other steps
necessary to effect the registration, offering and sale of the Registrable
Securities covered by the Shelf Registration Statement contemplated hereby.

        (u) The Company may require each Electing Holder with respect to a Shelf
Registration Statement to furnish to the Company such information regarding the
Electing Holder and the distribution of Registrable Securities held by such
Electing Holder as may be required by applicable law or regulation for inclusion
in such Shelf Registration Statement and the Company may exclude from such
registration the Registrable Securities of any Electing Holder that fails to
furnish such information within a reasonable time after receiving such request.

        4. Registration Expenses. Except as otherwise provided in Section 6, the
Company shall bear all fees and expenses incurred in connection with the
performance of its obligations under Sections 2 and 3 hereof and shall bear or
reimburse the Electing Holders for the reasonable fees and disbursements of a
single counsel selected by a plurality of all Electing Holders who own an
aggregate of not less than 25% of the Registrable Securities covered by the
Shelf Registration Statement to act as counsel therefor in connection therewith.
Each Electing Holder shall pay all underwriting discounts and commissions and
transfer taxes, if any, relating to the sale or disposition of such Electing
Holder's Registrable Securities pursuant to the Shelf Registration Statement.

        5. Indemnification and Contribution.

        (a) In connection with any Shelf Registration Statement, the Company
shall indemnify and hold harmless each Electing Holder, each Underwriter who
participates in an offering of Registrable Securities, each person, if any, who
controls any of such parties within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act and each of their respective directors,
officers, employees, trustees and agents, as follows:

              (i) against any and all loss, liability, claim, damage and expense
        whatsoever, including any amounts paid in settlement of any
        investigation, litigation, proceeding or claim, joint or several, as
        incurred, arising out of any untrue statement or alleged untrue
        statement of a material fact contained in any Shelf Registration
        Statement (or any amendment thereto) covering Registrable Securities,
        including all documents incorporated therein by reference, or the
        omission or alleged omission therefrom of a material fact required to be
        stated therein or necessary to make the statements therein not
        misleading or arising out of any untrue statement or alleged untrue
        statement of a material fact contained in any Prospectus (or any
        amendment or supplement thereto) or the omission or alleged omission
        therefrom of a material fact necessary in order to make the statements
        therein, in the light of the circumstances under which they were made,
        not misleading; provided, that the Company shall not be liable under
        this clause (i) for any settlement of any action effected without its
        written consent, which consent shall not be unreasonably withheld; and

                                       11
<PAGE>   12

              (ii) against any and all expenses whatsoever, as incurred
        (including reasonable fees and disbursements of counsel chosen by the
        Electing Holders, such Electing Holder or any Underwriter (except to the
        extent otherwise expressly provided in Section 5(c) hereof)), reasonably
        incurred in investigating, preparing or defending against any
        litigation, or any investigation or proceeding by any court or
        governmental agency or body, commenced or threatened, or any claim
        whatsoever based upon any such untrue statement or omission, or any such
        alleged untrue statement or omission, to the extent that any such
        expense is not paid under subparagraph (i) of this Section 5(a);

provided that this indemnity shall not apply to any loss, liability, claim,
damage or expense to the extent arising out of an untrue statement or omission
or alleged untrue statement or omission made in reliance upon and in conformity
with written information furnished to the Company by such Electing Holder or any
Underwriter in writing expressly for use in the Shelf Registration Statement (or
any amendment thereto) or any Prospectus (or any amendment or supplement
thereto). Any amounts advanced by the Company to an indemnified party pursuant
to this Section 5 as a result of such losses shall be returned to the Company if
it shall be finally determined by such a court in a judgment not subject to
appeal or final review that such indemnified party was not entitled to
indemnification by the Company.

        (b) Each Electing Holder shall agree, severally and not jointly, to
indemnify and hold harmless the Company, each Underwriter who participates in an
offering of Registrable Securities and the other Electing Holders and each of
their respective directors, officers (including each officer of the Company who
signed the Shelf Registration Statement), employees, trustees and agents and
each Person, if any, who controls the Company, any Underwriter or any other
Electing Holder within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act, from and against any and all loss, liability,
claim, damage and expense whatsoever described in the indemnity contained in
Section 5(a)(i) and (ii) hereof, as incurred, but only with respect to untrue
statements or omissions, or alleged untrue statements or omissions, made in the
Shelf Registration Statement (or any amendment thereto) or any Prospectus (or
any amendment or supplement thereto) in reliance upon and in conformity with
written information furnished to the Company by such Electing Holder expressly
for use in the Shelf Registration Statement (or any amendment thereto) or any
Prospectus (or any amendment or supplement thereto); provided, however, that, no
such Electing Holder shall be liable for any claims hereunder in excess of the
amount of net proceeds received by such Electing Holder from the sale of
Registrable Securities pursuant to the Shelf Registration Statement.

        (c) Each indemnified party shall give prompt notice to each indemnifying
party of any action commenced against it in respect of which indemnity may be
sought hereunder, enclosing a copy of all papers served on such indemnified
party, but failure to so notify an indemnifying party shall not relieve it of
any liability which it may have to the indemnified party otherwise than on
account of this indemnity agreement. An indemnifying party may participate at
its own expense in the defense of any such action. If an indemnifying party so
elects within a reasonable time after receipt of such notice, such indemnifying
party, jointly with any other indemnifying party, may assume the defense of such
action with counsel chosen by it and approved by the indemnified party or
parties defendant in such action, provided that if any such indemnified party
reasonably

                                       12
<PAGE>   13

determines that there may be legal defenses available to such indemnified party
which are different from or in addition to those available to such indemnifying
party or that representation of such indemnifying party and any indemnified
party by the same counsel would present a conflict of interest, then such
indemnifying party or parties shall not be entitled to assume such defense. If
an indemnifying party is not entitled to assume the defense of such action as a
result of the proviso to the preceding sentence, counsel for such indemnifying
party shall be entitled to conduct the defense of such indemnifying party and
counsel for each indemnified party or parties shall be entitled to conduct the
defense of such indemnified party or parties. If an indemnifying party assumes
the defense of an action in accordance with and as permitted by the provisions
of this paragraph, such indemnifying party shall not be liable for any fees and
expenses of counsel for the indemnified parties incurred thereafter in
connection with such action. In no event shall the indemnifying party or parties
be liable for the fees and expenses of more than one counsel (in addition to any
local counsel) separate from its own counsel for all indemnified parties in
connection with any one action or separate but similar or related actions in the
same jurisdiction arising out of the same general allegations or circumstances.

        (d) In order to provide for just and equitable contribution in
circumstances in which the indemnity provision provided for in this Section 5 is
for any reason held to be unavailable to an indemnified party although
applicable in accordance with its terms, then each indemnifying party shall
contribute to the aggregate losses, liabilities, claims, damages and expenses of
the nature contemplated by such indemnity agreement incurred by such indemnified
party, as incurred; provided that no Person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any Person that was not guilty of such
fraudulent misrepresentation. Each such indemnifying party shall contribute to
such aggregate losses, liabilities, claims, damages and expenses of such
indemnified party of the nature contemplated by such indemnity agreement in such
proportion as shall be appropriate to reflect the relative fault of such
indemnifying party, on the one hand, and such indemnified party, on the other
hand, with respect to the statements or omissions which resulted in such loss,
liability, claim, damage or expense, or action in respect thereof, as well as
any other relevant equitable considerations. The relative fault of an
indemnifying party, on the one hand, and of an indemnified party, on the other
hand, shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by such
indemnifying party, on the one hand, or by or on behalf of such indemnified
party, on the other, and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.
The Company, the Purchasers and the Holders of the Registrable Securities agree
that it would not be just and equitable if contribution pursuant to this Section
5(d) were to be determined by pro rata allocation or by any other method of
allocation that does not take into account the relevant equitable
considerations. For purposes of this Section 5(d), each director, officer,
employee, trustee, agent and Person, if any, who controls a Purchaser or Holder
within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act shall have the same rights to contribution as such Purchaser or
Holder, as the case may be, and each director, officer, employee, trustee and
agent of the Company, and each Person, if any, who controls the Company within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
Act shall have the same rights to

                                       13
<PAGE>   14

contribution as the Company. No party shall be liable for contribution with
respect to any action, suit, proceeding or claim settled without its written
consent, which consent shall not be unreasonably withheld.

        (e) The Company may require, as a condition to including any Registrable
Securities in any Registration Statement filed and to entering into any
underwriting agreement with respect thereto, that the Company shall have
received an undertaking reasonably satisfactory to it from the holder of such
Registrable Securities and from each Underwriter named in any such underwriting
agreement, severally and not jointly, to comply with the provisions of
paragraphs (a) through (d) of this Section 5.

        The indemnity and contribution provisions contained in this Section 5
shall remain operative and in full force and effect regardless of (i) any
termination of this Agreement, (ii) any investigation made by or on behalf of
the Managing Underwriters, if any, any Electing Holder or any Person controlling
any Electing Holder, or by or on behalf of the Company, its officers or
directors or any Person controlling the Company and (iii) any sale of
Registrable Securities pursuant to the Shelf Registration Statement.

        6. Underwritten Offering. The Electing Holders who desire to do so may
sell Registrable Securities in an underwritten offering upon request to the
Company. In any such underwritten offering, the investment banker or bankers and
manager or managers that will administer the offering will be selected by, and
the underwriting arrangements with respect thereto will be approved by the
Holders of a majority of the Registrable Securities to be included in such
offering; provided, however, that (i) such investment bankers and managers and
underwriting arrangements must be reasonably satisfactory to the Company and
(ii) the Company shall not be obligated to arrange for more than one
underwritten offering during the Effectiveness Period. No Holder may participate
in any underwritten offering contemplated hereby unless such Holder (a) agrees
to sell such Holder's Registrable Securities in accordance with any approved
underwriting arrangements, (b) completes and executes all reasonable
questionnaires, powers of attorney, indemnities, underwriting agreements,
lock-up letters and other documents required under the terms of such approved
underwriting arrangements and (c) at least 20% of the outstanding Registrable
Securities are included in such underwritten offering. The Holders participating
in any underwritten offering shall be responsible for any expenses customarily
borne by selling securityholders, including underwriting discounts and
commissions and fees and expenses of counsel to the selling securityholders and
shall reimburse the Company for the fees and disbursements of their counsel,
their independent public accountants and any printing expenses incurred in
connection with such underwritten offerings. Notwithstanding the foregoing or
the provisions of Section 3(o) hereof, upon receipt of a request from the
Managing Underwriter or a representative of Holders of a majority of the
Registrable Securities outstanding to prepare and file an amendment or
supplement to the Shelf Registration Statement and Prospectus in connection with
an underwritten offering, the Company may delay the filing of any such amendment
or supplement for up to 90 days if the Company in good faith has a valid
business reason for such delay.

        7. Liquidated Damages

                                       14
<PAGE>   15

        (a) Pursuant to Section 2(a) hereof, the Company may, upon written
notice to all the Holders, postpone having the Shelf Registration Statement
declared effective for a reasonable period not to exceed 90 days if the Company
possesses material non-public information, the disclosure of which would have a
material adverse effect on the Company and its subsidiaries taken as a whole.
Notwithstanding any such postponement, if (i) on or prior to the 90th day
following the Closing Date, a Shelf Registration Statement has not been filed
with the Commission or (ii) on or prior to the 180th day following the Closing
Date, such Shelf Registration Statement is not declared effective by the
Commission (each, a "Registration Default"), the Company shall be required to
pay liquidated damages ("Liquidated Damages"), from and including the day
following such Registration Default until such Shelf Registration Statement is
either so filed or so filed and subsequently declared effective, as applicable,
or, if earlier, the end of the Effectiveness Period, at a rate per annum equal
to an additional one-quarter of one percent (0.25%) of the principal amount of
Registrable Securities, to and including the 90th day following such
Registration Default and one-half of one percent (0.5%) thereof from and after
the 91st day following such Registration Default.

        (b) In the event that the Shelf Registration Statement ceases to be
effective (or the Holders of Registrable Securities are otherwise prevented or
restricted by the Company from effecting sales pursuant thereto) (an "Effective
Failure") for more than 45 days, whether or not consecutive, in any 90-day
period, or 90 days, whether or not consecutive, during any 12-month period, then
the Company shall pay Liquidated Damages at a rate per annum equal to an
additional one-half of one percent (0.5%) from the 46th day of the applicable
90-day period or the 91st day of the applicable 12-month period, as the case may
be, that such Shelf Registration Statement ceases to be effective (or the
Holders of Registrable Securities are otherwise prevented or restricted by the
Company from effecting sales pursuant thereto) until the earlier of (i) the time
the Shelf Registration Statement again becomes effective or the Holders of
Registrable Securities are again able to make sales under the Shelf Registration
Statement or (2) the time the Effectiveness Period expires. For the purpose of
determining an Effective Failure, days on which the Company has been obligated
to pay Liquidated Damages in accordance with the foregoing in respect of a prior
Effective Failure within the applicable 90-day or 12-month period, as the case
may be, shall not be included.

        (c) In the event the Company fails to file a post-effective amendment to
the Shelf Registration Statement, or the post-effective amendment is not
declared effective, within the periods required by Section 3(b)(4), the Company
shall pay Liquidated Damages at a rate per annum equal to an additional one-half
of one percent (0.5%) from and including the date of such Registration Default
until such time as such Registration Default is cured.

        (d) Any amounts to be paid as Liquidated Damages pursuant to paragraphs
(a), (b) or (c) of this Section shall be paid semi-annually in arrears, with the
first semi-annual payment due on the first Interest Payment Date (as defined in
the Indenture), as applicable, following the date of such Registration Default.
Such Liquidated Damages will accrue (1) in respect of the Securities at the
rates set forth in paragraphs (a), (b) or (c) of this Section, as applicable, on
the principal amount of the Securities and (2) in respect of the Common Stock
issued upon conversion of the Securities,

                                       15
<PAGE>   16

at the rates set forth in paragraphs (a), (b) or (c) of this Section, as
applicable, applied to the Conversion Price (as defined in the Indenture) at
that time.

        (e) Except as provided in Section 2(d), the Liquidated Damages as set
forth in this Section 7 shall be the exclusive monetary remedy available to the
Holders of Registrable Securities for such Registration Default or Effective
Failure. In no event shall the Company be required to pay Liquidated Damages in
excess of the applicable maximum amount of one-half of one percent (0.5%) set
forth above, regardless of whether one or multiple Registration Defaults exist.

        8. Miscellaneous.

        (a) Other Registration Rights. The Company may have granted and may in
the future grant registration rights that would permit any Person that is a
third party the right to piggy-back on any Shelf Registration Statement,
provided that if the Managing Underwriter, if any, of such offering notifies the
Electing Holders that the total amount of securities which they and the holders
of such piggy-back rights intend to include in any Shelf Registration Statement
is so large as to materially adversely affect the success of such offering
(including the price at which such securities can be sold), then only the
amount, the number or kind of securities to be offered for the account of
holders of such piggy-back rights will be reduced to the extent necessary to
reduce the total amount of securities to be included in such offering to the
amount, number or kind recommended by the Managing Underwriter prior to any
reduction in the amount of Registrable Securities to be included.

        (b) Amendments and Waivers. The provisions of this Agreement, including
the provisions of this sentence, may not be amended, qualified, modified or
supplemented, and waivers or consents to departures from the provisions hereof
may not be given, unless the Company has obtained the written consent of
Goldman, Sachs & Co.

        (c) No Inconsistent Agreements. The Company has not entered into, and on
or after the date of this Agreement will not enter into, any agreement which is
inconsistent with the rights granted to the Holders of Registrable Securities in
this Agreement or otherwise conflicts with the provisions hereof. The rights
granted to the Holders hereunder do not in any way conflict with and are not
inconsistent with the rights granted to the holders of the Company's other
issued and outstanding securities under any such agreements.

        (d) Notices. All notices and other communications provided for or
permitted hereunder shall be made in writing by hand-delivery, first-class mail,
telex, telecopier, or air courier guaranteeing overnight delivery:

              (1) if to a Holder, at the most current address given by such
        Holder to the Company in accordance with the provisions of this Section
        8(d);

              (2) if to the Purchasers, initially at the address set forth in
        the Purchase Agreement; and

                                       16
<PAGE>   17

              (3) if to the Company, initially at its address set forth in the
        Purchase Agreement.

All such notices and communications shall be deemed to have been duly given when
received.

        The Purchasers or the Company by notice to the other may designate
additional or different addresses for subsequent notices or communications.

        (e) Successors and Assigns. This Agreement shall inure to the benefit of
and be binding upon the successors and assigns of each of the parties and the
Holders, including, without the need for an express assignment or any consent by
the Company thereto, subsequent Holders of Registrable Securities. The Company
hereby agrees to extend the benefits of this Agreement to any Holder of
Registrable Securities and any such Holder may specifically enforce the
provisions of this Agreement as if an original party hereto.

        (f) Counterparts. This Agreement may be executed in any number of
counterparts and by the parties hereto in separate counterparts, each of which
when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same agreement.

        (g) Headings. The headings in this agreement are for convenience of
reference only and shall not limit or otherwise affect the meaning hereof.

        (h) Governing Law. This agreement shall be governed by and construed in
accordance with the laws of the State of New York, without giving effect to any
provisions relating to conflicts of laws.

        (i) Severability. In the event that any one or more of the provisions
contained herein, or the application thereof in any circumstances, is held
invalid, illegal or unenforceable in any respect for any reason, the validity,
legality and enforceability of any such provision in every other respect and of
the remaining provisions hereof shall not be in any way impaired or affected
thereby, it being intended that all of the rights and privileges of the parties
hereto shall be enforceable to the fullest extent permitted by law.

                                       17
<PAGE>   18

        Please confirm that the foregoing correctly sets forth the agreement
between the Company and you.

                                       Very truly yours,

                                       COR THERAPEUTICS, INC.

                                       By: /s/ PETER S. RODDY
                                          ------------------------------------
                                            Name:  Peter S. Roddy
                                            Title: Vice President, Finance

The foregoing Registration Rights Agreement is hereby confirmed and accepted as
of the date first above written.

Goldman, Sachs & Co.,
Chase H&Q, A Division of Chase Securities Inc.,
CIBC World Markets Corp.,
FleetBoston Robertson Stephens Inc.,
Warburg Dillon Read LLC,

By: /s/ GOLDMAN, SACHS & CO.
   -----------------------------------
         (Goldman, Sachs & Co.)

                                       18
<PAGE>   19

                                                                      Appendix A

                             COR THERAPEUTICS, INC.

                         INSTRUCTION TO DTC PARTICIPANTS

                                (Date of Mailing)

                     URGENT - IMMEDIATE ATTENTION REQUESTED

                          DEADLINE FOR RESPONSE: [DATE]

        The Depository Trust Company ("DTC") has identified you as a DTC
Participant through which beneficial interests in the COR Therapeutics, Inc.
(the "Company") 5.00% Convertible Subordinated Notes due March 1, 2007 (the
"Notes") are held. The Notes are identified by CUSIP No. 217753AA0.

        In accordance with the terms of the Registration Rights Agreement, dated
as of February 17, 2000, between the Company and the Purchasers named therein
(the "Registration Rights Agreement"), the Company is in the process of
registering the Notes and the shares of common stock, par value $.0001 per share
(together, the "Securities"), issuable upon conversion thereof, under the
Securities Act of 1933, as amended, for resale by the beneficial owners thereof.
In order to have their Securities included in the registration statement, the
beneficial owners, INCLUDING BENEFICIAL OWNERS RESIDENT OUTSIDE THE UNITED
STATES, must complete and return the enclosed Notice of Registration Statement
and Selling Securityholder Questionnaire (the "Notice and Questionnaire").

        It is important that beneficial owners of the Securities receive a copy
of the enclosed materials as soon as possible as their rights to have the
Securities included in the registration statement depend upon their returning
the Notice and Questionnaire by [DEADLINE FOR RESPONSE]. Please forward a copy
of the enclosed documents to each beneficial owner that holds interests in the
Securities through you. If you require more copies of the enclosed materials or
have any questions pertaining to this matter, please contact:

                     COR Therapeutics, Inc.
                     256 East Grand Avenue
                     South San Francisco, California  94080
                     Attention:  Corporate Counsel
                     Telephone:  (650) 246-7315
                     Fax:  (650) 244-9208.

                                      A-1
<PAGE>   20

                        NOTICE OF REGISTRATION STATEMENT
                    AND SELLING SECURITYHOLDER QUESTIONNAIRE

                                      A-2
<PAGE>   21

                             COR Therapeutics, Inc.

                        Notice of Registration Statement
                                       and
                      Selling Securityholder Questionnaire
                                     (Date)

        COR Therapeutics, Inc. (the "Company") has filed or intends shortly to
file with the United States Securities and Exchange Commission (the
"Commission") a preliminary registration statement on Form S-3 (the "Shelf
Registration Statement") for the registration and resale under the United States
Securities Act of 1933, as amended (the "Securities Act"), of the Company's
5.00% Convertible Subordinated Notes due March 1, 2007 (CUSIP No. 21753AA0) (the
"Notes"), and Common Stock issuable upon conversion thereof, in accordance with
the terms of the Registration Rights Agreement, dated as of February 24, 2000
(the "Registration Rights Agreement"), between the Company and the purchasers
named therein (the "Purchasers"). A copy of the Registration Rights Agreement
has been sent to each of the Purchasers. All capitalized terms not otherwise
defined herein shall have the meanings ascribed thereto in the Registration
Rights Agreement.

        In order to have Registrable Securities included in the Shelf
Registration Statement (or a supplement or amendment thereto), this Notice of
Registration Statement and Selling Securityholder Questionnaire ("Notice and
Questionnaire") must be completed, executed and delivered to the Company at the
address set forth herein for receipt ON OR BEFORE [insert date that is 30 days
from the Notice date] (the "Questionnaire Deadline"). Unless the Company
otherwise consents, beneficial owners of the Registrable Securities who do not
complete, execute and return this Notice and Questionnaire by such date (i) will
not be named as selling securityholders in the Shelf Registration Statement (or
a supplement or amendment thereto) and related Prospectus and (ii) may not sell
their Registrable Securities pursuant thereto. Beneficial owners of Registrable
Securities not who have returned a Notice and Questionnaire by the Questionnaire
Deadline may, however, receive another Notice and Questionnaire from the Company
upon request. Following its receipt of a completed and signed Notice and
Questionnaire, the Company will include the Registrable Securities covered
thereby in the Shelf Registration Statement subject to restrictions on the
timing and number of supplements to the Shelf Registration Statement provided in
the Registration Rights Agreement.

        Certain legal consequences arise from being named as a selling
securityholder in the Shelf Registration Statement and related Prospectus.
Accordingly, holders and beneficial owners of Registrable Securities are advised
to consult their own securities law counsel regarding the consequences of being
named or not being named as a selling securityholder in the Shelf Registration
Statement and related Prospectus.

        The term "Registrable Securities" is defined in the Registration Rights
Agreement to mean all or any portion of the Notes issued under the Trust
Indenture and the Common Stock issuable upon

                                      A-3
<PAGE>   22

conversion of such Notes, provided, however, that a security ceases to be a
Registrable Security when it is no longer a Restricted Security.

        The term "Restricted Security" is defined in the Registration Rights
Agreement to mean any Note or Common Stock issuable upon conversion thereof
except any such Note or Common Stock which (i) has been registered pursuant to
an effective registration statement under the Securities Act and sold in a
manner contemplated by the Shelf Registration Statement, (ii) has been
transferred in compliance with Rule 144 under the Securities Act (or any
successor provision thereto) or is transferable pursuant to paragraph (k) of
Rule 144 (or any successor provision thereto) or (iii) has otherwise been
transferred and a new Note or share of Common Stock not subject to transfer
restrictions under the Securities Act has been delivered by or on behalf of the
Company in accordance with the Indenture.

                                    ELECTION

        The undersigned holder (the "Selling Securityholder") of Registrable
Securities hereby elects to include in the Shelf Registration Statement the
Registrable Securities beneficially owned by it and listed below in Item (3)
(unless otherwise specified under Item 3). The undersigned, by signing and
returning this Notice and Questionnaire, agrees to be bound with respect to such
Registrable Securities by the terms and conditions of this Notice and
Questionnaire and the Registration Rights Agreement, including, without
limitation, Section 5 of the Registration Rights Agreement, as if the
undersigned Selling Securityholder were an original party thereto.

        Upon any sale of Registrable Securities pursuant to the Shelf
Registration Statement, the Selling Securityholder will be required to deliver
to the Company and the Trustee the Notice of Transfer (completed and signed) set
forth in Exhibit 1 attached to this Notice and Questionnaire and hereby
undertakes to do so.

        The Selling Securityholder hereby provides the following information to
the Company and represents and warrants that such information is accurate and
complete:

                                      A-4
<PAGE>   23

                                  QUESTIONNAIRE

(1)     (a) Full Legal Name of Selling Securityholder:

        ------------------------------------------------------------------------

        (b)   Full Legal Name of Registered Holder (if not the same as in (a)
              above) of Registrable Securities Listed in (3) Below:

        ------------------------------------------------------------------------

        (c)   Full Legal Name of DTC Participant (if applicable and if not the
              same as (b) above) Through Which Registrable Securities Listed in
              (3) Below are Held:

        ------------------------------------------------------------------------

(2)     Address for Notices to Selling Securityholder:

        ------------------------------------------------------------------------

        ------------------------------------------------------------------------

        ------------------------------------------------------------------------

        Telephone:
                  --------------------------------------------------------------

        Fax:
            --------------------------------------------------------------------

        Contact:
                ----------------------------------------------------------------

(3)     Beneficial Ownership of Registrable Securities:

        Except as set forth below, the undesigned Selling Securityholder does
        not beneficially own any Notes or Common Stock previously issued upon
        conversion, repurchase or redemption of any Note.

        Principal amount of Notes beneficially owned:
                                                     --------------------------

        Number of shares of Common Stock beneficially owned and issued to date
        upon conversion, repurchase or redemption of Notes (if any):
                                                                    ------------

        Principal amount of Notes which the undersigned wishes to be included in
        the Shelf Registration Statement:
                                         ---------------------------------------

        Number of shares of Common Stock (if any) issued upon conversion,
        repurchase or redemption of Registrable Securities which are to be
        included in the Shelf Registration Statement:

                                      A-5

<PAGE>   24

        ------------------------------------------------------------------------

(4)     Other shares of Common Stock or other Notes of the Company owned by the
        Selling Securityholder:
                               -------------------------------------------------

        Except as set forth below, and under item (3) above, the undersigned
        Selling Securityholder is not the beneficial or registered owner of any
        shares of Common Stock or any other securities of the Company.

State any exceptions here:

(5)     Relationships with the Company:

        Except as set forth below, neither the Selling Securityholder nor any of
        its affiliates, officers, director or principal equity holders (5% or
        more) has held any position or office or has had any other material
        relationship with the Company (or its predecessors or affiliates) during
        the past three years.

State any exceptions here:

(6)     Plan of Distribution:

        Except as set forth below, the undersigned Selling Securityholder
        intends to distribute the Registrable Securities listed above in Item
        (3) only as follows (if at all): Such Registrable Securities may be sold
        from time to time directly by the undersigned Selling Securityholder or,
        alternatively, through underwriters, broker-dealers or agents. Such
        Registrable Securities may be sold in one or more transactions at fixed
        prices, at prevailing market prices at the time of sale, at varying
        prices determined at the time of sale, or at negotiated prices. Such
        sales may be effected in transactions (which may involve crosses or
        block transactions) (i) on any national securities exchanges or U.S.
        inter-dealer quotation system of a registered national securities
        association on which the Registrable Securities may be listed or quoted
        at the time of sale, (ii) in the over-the-counter market, (iii) in
        transactions otherwise than on such exchanges or services or in the
        over-the-counter market, or (iv) through the writing of options. In
        connection with sales of the Registrable Securities or otherwise, the
        Selling Securityholder may enter into hedging transactions with
        broker-dealers, which may in turn engage in short sales of the
        Registrable Securities in the course of hedging the positions they
        assume. The Selling Securityholders may also sell Registrable Securities
        short and deliver Registrable Securities to close out such short
        positions, or loan or pledge Registrable Securities to broker-dealers
        that in turn may sell such securities.

State any exceptions here:

                                      A-6
<PAGE>   25

        Note: In no event may such method(s) of distribution take the form of an
underwritten offering of the Registrable Securities without the prior agreement
of the Company.

        By signing below, the Selling Securityholder acknowledges that it
understands its obligation to comply, and agrees that it will comply, with the
prospectus delivery and other provisions of the Securities Act and Exchange Act
and the respective rules and regulations thereunder, particularly Regulation M.

              In the event that the Selling Securityholder transfers all or any
portion of the Registrable Securities listed in Item (3) above after the date on
which such information is provided to the Company, the Selling Securityholder
agrees to notify the transferee(s) at the time of the transfer of its rights and
obligations under this Notice and Questionnaire and the Registration Rights
Agreement.

                                      A-7
<PAGE>   26

              By signing below, the Selling Securityholder consents to the
disclosure of the information contained herein in its answers to Items (1)
through (6) above and the inclusion of such information in the Shelf
Registration Statement and related Prospectus. The Selling Securityholder
understands that such information will be relied upon by the Company in
connection with the preparation of the Shelf Registration Statement and related
Prospectus.

              In accordance with the Selling Securityholder's obligation under
the Registration Rights Agreement to provide such information as may be required
by law for inclusion in the Shelf Registration Statement, the Selling
Securityholder agrees to promptly notify the Company of any inaccuracies or
changes in the information provided herein which may occur subsequent to the
date hereof at any time while the Shelf Registration Statement remains in
effect. All notices hereunder and pursuant to the Registration Rights Agreement
shall be made in writing by hand delivery, first-class mail, or air courier
guaranteeing overnight delivery as follows:

              To the Company:

                     COR Therapeutics, Inc.
                     256 East Grand Avenue
                     South San Francisco, California 94080
                     Attention: General Counsel

              Once this Notice and Questionnaire is executed by the Selling
Securityholder and received by the Company, the terms of this Notice and
Questionnaire, and the representations and warranties contained herein, shall be
binding on, shall inure to the benefit of and shall be enforceable by the
respective successors, heirs, personal representatives, and assigns of the
Company and the Selling Securityholder with respect to the Registrable
Securities beneficially owned by such Selling Securityholder and listed in Item
(3) above. This Agreement shall be governed in all respects by the laws of the
State of New York.

              IN WITNESS WHEREOF, the undersigned, by authority duly given, has
caused this Notice and Questionnaire to be executed and delivered either in
person or by its duly authorized agent.

Dated:
      --------------------------------------------------------

                     -----------------------------------------
                     Selling Securityholder
                     (Print/type full legal name of beneficial
                     owner of Registrable Securities)

                     By:
                        --------------------------------------

                     Name:
                          ------------------------------------

                     Title:
                           -----------------------------------

                                      A-8
<PAGE>   27

              PLEASE RETURN THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE
FOR RECEIPT ON OR BEFORE [DEADLINE FOR RESPONSE] TO THE COMPANY AT:

                     COR Therapeutics, Inc.
                     256 East Grand Avenue
                     South San Francisco, California 94080
                     Attention: General Counsel

                                      A-9
<PAGE>   28

                                                                       EXHIBIT 1
                                                                   to Appendix A

              NOTICE TO TRANSFER PURSUANT TO REGISTRATION STATEMENT

Firstar Bank, N.A.
101 E. 5th Street
12th Floor Corporate Trust
St. Paul, MN 55101

COR Therapeutics, Inc.
256 East Grand Avenue
South San Francisco, California 94080
Attention:  General Counsel

Re: 5.00% Convertible Subordinated Notes

    due March 1, 2007 (the "Notes")

Dear Sirs:

        Please be advised that                     has transferred $
aggregate principal amount of the above-referenced Notes or shares of the
Company's Common Stock, issued on conversion, repurchase or redemption of Notes,
pursuant to the Registration Statement Form S-3 (File No. 333-          ) filed
by the Company.

        We hereby certify that the prospectus delivery requirements, if any, of
the Securities Act of 1933, as amended, have been satisfied with respect to the
transfer described above and that the above-named beneficial owner of the Notes
or Common Stock is named as a selling securityholder in the Prospectus dated or
in amendments or supplements thereto, and that the aggregate principal amount of
the Notes or number of Common Stock transferred are [a portion of] the Notes or
Common Stock listed in such Prospectus as amended or supplemented opposite such
owner's name.

                                      A-10
<PAGE>   29

Dated:                                           Very truly yours,
      ------------------------------

                                       ------------------------------------
                                                     (Name)

                                       By:
                                          ---------------------------------
                                              (Authorized Signature)

                                      A-11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}]]